WO2006027628A2 - Naphthalimide derivatives as antiviral agents - Google Patents

Naphthalimide derivatives as antiviral agents Download PDF

Info

Publication number
WO2006027628A2
WO2006027628A2 PCT/GB2005/050145 GB2005050145W WO2006027628A2 WO 2006027628 A2 WO2006027628 A2 WO 2006027628A2 GB 2005050145 W GB2005050145 W GB 2005050145W WO 2006027628 A2 WO2006027628 A2 WO 2006027628A2
Authority
WO
WIPO (PCT)
Prior art keywords
benzo
amino
cfe
dioxo
isoquinolin
Prior art date
Application number
PCT/GB2005/050145
Other languages
French (fr)
Other versions
WO2006027628A3 (en
Inventor
Steve Carroll
Jose Ignacio Martin Hernando
Savina Malancona
Giovanni Migliaccio
Frank Narjes
David Olsen
Jesus Maria Ontoria Ontoria
Michael Rowley
Vincenzo Summa
Original Assignee
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa, Merck & Co., Inc. filed Critical Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa
Publication of WO2006027628A2 publication Critical patent/WO2006027628A2/en
Publication of WO2006027628A3 publication Critical patent/WO2006027628A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems

Definitions

  • This invention relates to compounds which can act as inhibitors of viral polymerases, especially the hepatitis C virus (HCV) polymerase, to uses of such compounds in the treatment and prevention of infection by hepatitis C virus, and to their preparation.
  • HCV hepatitis C virus
  • HCV hepatitis C virus
  • NANB-H non-A, non-B hepatitis
  • Some 1% of the human population of the planet is believed to be affected. Infection by the virus can result in chronic hepatitis and cirrhosis of the liver, and may lead to hepatocellular carcinoma.
  • RNA-dependent RNA polymerase plays an essential role in replication of the virus and is therefore an important target in the fight against hepatitis C.
  • naphthalimide derivatives have been disclosed in the art but none are disclosed as being useful as inhibitors of hepatitis C virus (HCV) polymerase.
  • R, R 1 and R 2 are as defined therein, as glycoprotein IbIX antagonists.
  • X 1 , Y, A 1 , R 1 , R 2 and e are as defined therein. These compounds are disclosed as being useful as antitumour agents. 4-alkylamino-N-alkylnaphthalic-l,8-imides are also disclosed in, for instance, Alexiou et al. J. Chem. Research (S), 2000, 208-210; Ghorbanian et al. J. Chem. Technol. BiotechnoL, 75:1127-1134 (2000); and Qian et al. Dyes and Pigments, 11(1989), 13-20.
  • naphthalimide derivatives act as inhibitors of the hepatitis C virus (HCV) polymerase enzyme.
  • R 1 is Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) 0-3 C 3-7 cycloalkyl, (CH 2 ) 0-3 Het, (CH 2 ) 0-3 aryl or (CH 2 ) 0-3 heteroaryl, optionally substituted by halogen, hydroxy, Ci -6 alkyl, Ci -6 alkoxy, C 2-6 alkenyl, CN, (CH 2 ) 0-3 ⁇ (CH 2 )o -3 aryl, S(Ci -6 alkyl), S(O)(Ci -6 alkyl), S(O) 2 (Ci -6 alkyl), S-heteroaryl, S(O)heteroaryl, S(O) 2 heteroaryl, S-aryl, S(O)aryl, S(O) 2 aryl, SO 2 NR 4 R 5 , CO 2 R 4 , CONR 4 R 5 , NR 4 COR 5 ,
  • R 4 , R 5 and R 21 are each independently selected from hydrogen, Ci -6 alkyl, (CH 2 ) 0-3 Het, (CH 2 )o -3 aryl, (CH 2 ) 0-3 heteroaryl and SO 2 (Ci -6 alkyl), optionally substituted by 1 to 5 halogen atoms and/or 1 or 2 groups selected from hydroxy, Ci -6 alkyl, NH 2 and Ci -6 alkoxy;
  • R 2 is halogen, hydroxy, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, Ci -6 alkoxy, (CH 2 ) 0-3 C 3-8 cycloalkyl, (CH 2 )o -3 aryl, CN, NO 2 , NR 6 R 7 , OR 8 , C(O)C i -6 alkyl, CO 2 H, CO 2 R 8 , CONR 8 R 20 , NR 21 COR 8 , NR 21 SO 2 R 8 , NR 8 CONR 20 , SR 8 , SOR 8 , SO 2 R 8 or SO 2 NR 8 R 20 , where said Ci -6 alkyl, C 2-6 alkenyl, Ci -6 alkoxy and aryl groups are optionally substituted by 1 or 2 groups selected from halogen, hydroxy, Ci -6 alkyl, Ci -6 alkoxy, NH 2 , SO 2 NR 6 R 7 , CO 2 R 6 and CONR 6 R 7
  • R 6 and R 7 are each independently selected from hydrogen, Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 )o -3 C 3-7 cycloalkyl, (CH 2 ) 0-3 Het, (CH 2 ) 0-3 aryl, (CH 2 ) 0-3 heteroaryl, (CH 2 ) 0-3 OR 9 , (CH 2 ) 0-3 SR 9 , (CH 2 ) O-3 NR 10 R 11 , -C(CH 2 OH) 3 , COR 22 , C(O)C(O)OCi -6 alkyl, CO 2 R 22 , CONR 22 R 23 , SO 2 R 22 and SO 2 NR 22 R 23 , where said Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, cycloalkyl, Het, aryl and heteroaryl groups are optionally substituted by 1 or 2 groups selected from halogen, hydroxy, Ci -6
  • R 18 and R 19 are each independently selected from hydrogen, Ci -6 alkyl, C 2-6 alkenyl, (CH 2 ) 0-3 C 3-7 cycloalkyl, (CH 2 ) 0-3 Het, (CH 2 ) 0-3 aryl, (CH 2 ) 0-3 heteroaryl, (CH 2 ) 0-3 OR 9 , (CH 2 ) 0-3 SR 9 , (CH 2 ) O-3 NR 10 R 11 , -C(CH 2 OH) 3 , where said Ci -6 alkyl, C 2-6 alkenyl and Ci -6 alkoxy groups are optionally substituted by halogen or hydroxy;
  • R 9 , R 10 and R 11 are each independently selected from hydrogen, Ci -6 alkyl, C 2-6 alkenyl, C(O)Ci -6 alkyl and aryl; or R 6 , R 7 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, which ring optionally contains 1, 2 or 3 additional heteroatoms selected from O and S or a group S(O), S(O) 2 or NR 12 , where R 12 is hydrogen, Ci -6 alkyl, C 2-6 alkenyl or aryl, and which ring is optionally substituted by halogen, hydroxy, Ci -6 alkyl, C 2-6 alkenyl, Ci -6 alkoxy, oxo, SO 2 NR 18 R 19 , COR 18 , CO 2 R 18 or CONR 18 R 19 , and which ring is optionally bridged by -CH 2 - or -CH 2 CH 2 -;
  • R 8 , R 20 , R 22 and R 23 are each independently selected from hydrogen, Ci -6 alkyl, (CH 2 )i -3 OR 13 , (CH 2 ) 1-3 NR 14 R 15 , (CH 2 )o -3 aryl and (CH 2 ) 0-3 heteroaryl;
  • R 13 , R 14 and R 15 are each independently selected from hydrogen, Ci -6 alkyl, C 2-6 alkenyl, aryl, C(O)R 16 and C(O)OR 17 ;
  • R 16 , R 17 and R 24 are independently selected from hydrogen, Ci -6 alkyl and aryl;
  • R 25 is hydrogen, Ci -6 alkyl, (CH 2 )i -3 CO 2 H, (CH 2 ) 0-3 C 3-8 cycloalkyl, (CH 2 ) 0-3 phenyl or SO 2 (Ci -6 alkyl), where C 3-8 cycloalkyl and phenyl are optionally substituted by 1 to 3 groups selected from halogen, hydroxy or CO 2 H; n is O or 1 or 2, and when n is 2, the R 2 groups may be the same or different;
  • R a is hydrogen, o orr R R 22 a anndd R R aa a arree joined to form a 5- to 8-membered carbocyclic ring.
  • R 1 is Ci -6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, (CH 2 ) 0-3 C 3 - 7 cycloalkyl, (CH 2 ) 0-3 Het, (CH 2 ) 0-3 aryl or (CH 2 ) 0-3 heteroaryl, optionally substituted by halogen, hydroxy, Ci -6 alkyl, Ci -6 alkoxy, C 2-6 alkenyl, CN, S(Ci -6 alkyl), S(O)(Ci -6 alkyl), S(O) 2 (Ci -6 alkyl), S-heteroaryl, S(O)heteroaryl, S(O) 2 heteroaryl, S-aryl, S(O)aryl, S(O) 2 aryl, SO 2 NR 4 R 5 , CO 2 R 4 , CONR 4 R 5 , NR 4 COR 5 , NR 4 SO 2 R 5 or NR 4 CONR 5 where said Ci -6 al
  • R 4 , R 5 and R 21 are each independently selected from hydrogen, Ci -6 alkyl, (CH 2 ) 0-3 Het, (CH 2 ) 0-3 aryl and (CH 2 ) 0-3 heteroaryl;
  • R 2 is halogen, hydroxy, Ci -6 alkyl, C 2-6 alkenyl, Ci -6 alkoxy, CN, NO 2 , NR 6 R 7 , OR 8 , CO 2 H, CO 2 R 8 , CONR 8 R 20 , NR 21 COR 8 , NR 21 SO 2 R 8 , NR 8 CONR 20 , SR 8 , SOR 8 , SO 2 R 8 or SO 2 NR 8 R 20 , where said Ci -6 alkyl, C 2-6 alkenyl and Ci -6 alkoxy groups are optionally substituted by halogen, hydroxyl, SO 2 NR 6 R 7 , CO 2 R 6 or CONR 6 R 7 ;
  • R 6 and R 7 are each independently selected from hydrogen, Ci -6 alkyl, C 2-6 alkenyl, (CH 2 ) O-3 C 3-7 CyClOaIlCyI, (CH 2 ) 0-3 Het, (CH 2 ) 0-3 aryl, (CH 2 ) 0-3 heteroaryl, (CH 2 ) 0-3 OR 9 , (CH 2 ) 0-3 SR 9 , (CH 2 ) O-3 NR 10 R 11 , -C(CH 2 OH) 3 , COR 22 , CO 2 R 22 , CONR 22 R 23 , SO 2 R 22 and SO 2 NR 22 R 23 , where said Ci -6 alkyl, C 2-6 alkenyl, cycloalkyl, Het, aryl and heteroaryl groups are optionally substituted by halogen, hydroxy, SO 2 NR 18 R 19 , CO 2 R 18 or CONR 18 R 19 ;
  • R 18 and R 19 are each independently selected from hydrogen, Ci -6 alkyl, C 2-6 alkenyl, (CH 2 )o -3 C 3-7 cycloalkyl, (CH 2 ) 0-3 Het, (CH 2 ) 0-3 aryl, (CH 2 ) 0-3 heteroaryl, (CH 2 ) 0-3 OR 9 , (CH 2 ) 0-3 SR 9 , (CH 2 ) O-3 NR 10 R 11 , -C(CH 2 OH) 3 , where said Ci -6 alkyl, C 2-6 alkenyl and Ci -6 alkoxy groups are optionally substituted by halogen or hydroxy;
  • R 9 , R 10 and R 11 are each independently selected from hydrogen, Ci -6 alkyl, C 2-6 alkenyl, C(O)Ci -6 alkyl and aryl; or R 6 , R 7 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, which ring optionally contains 1, 2 or 3 additional heteroatoms selected from O and S or a group S(O), S(O) 2 or NR 12 , where R 12 is hydrogen, Ci -6 alkyl, C 2-6 alkenyl or aryl, and which ring is optionally substituted by halogen, hydroxy, Ci -6 alkyl, C 2-6 alkenyl or Ci -6 alkoxy, carboxyl, SO 2 NR 18 R 19 , COR 18 , CO 2 R 18 or CONR 18 R 19 ;
  • R 8 , R 20 , R 22 and R 23 are each independently selected from Ci -6 alkyl, (CH 2 )i -3 OR 13 , (CH 2 ) 1-3 NR 14 R 15 , (CH 2 )o -3 aryl and (CH 2 ) 0-3 heteroaryl;
  • R 13 , R 14 and R 15 are each independently selected from hydrogen, Ci -6 alkyl, C 2-6 alkenyl, aryl, C(O)R 16 and C(O)OR 17 ;
  • R 16 and R 17 are independently selected from hydrogen, Ci -6 alkyl and aryl; n is O or 1.
  • R 1 is (CH 2 ) 0-3 aryl, preferably (CH 2 ) 0-3 phenyl, more preferably phenyl or benzyl, most preferably phenyl, optionally substituted by halogen, hydroxy, Ci -6 alkyl, Ci -6 alkoxy, C 2-6 alkenyl, CN, S(C X-6 alkyl), S(O)(Ci -6 alkyl), S(O) 2 (Ci -6 alkyl), SO 2 NR 4 R 5 where R 4 and R 5 are as hereinbefore defined, preferably halogen, Ci -6 alkyl or Ci -6 alkoxy, more preferably, fluorine, chlorine, bromine, most preferably bromine.
  • R 1 When R 1 is substituted, it is preferably mono- or di-substituted, more preferably mono- substituted.
  • R 1 is phenyl and substituted, preferably it is substituted at the 3-position of the phenyl group, especially when it is mono-substituted.
  • R 2 is NR 6 R 7 where R 6 and R 7 are as hereinbefore defined.
  • R 6 and R 7 are independently selected from hydrogen, Ci -6 alkyl, (CH 2 ) 0-3 C 3 . 7 cycloalkyl, (CH 2 ) 0-3 ⁇ R 9 where R 9 is as hereinbefore defined. More preferably, one of R 6 and R 7 is hydrogen and the other is selected from Ci -6 alkyl, (CH 2 )o -3 C 3-7 cycloalkyl or (CH 2 V 3 OR 9 , especially (CH 2 ) 2 OR 9 .
  • R 9 is selected from hydrogen, C ⁇ alkyl and aryl, more preferably hydrogen.
  • n 1, preferably the R 2 group is at the 4-position of the naphthalimide moiety.
  • R 1 is (CH 2 ) 0-3 aryl, more preferably phenyl, optionally substituted by halogen, hydroxy, Ci -6 alkyl, Ci -6 alkoxy, C 2-6 alkenyl, CN, S(Ci -6 alkyl), S(O)(Ci -6 alkyl), S(O) 2 (Ci -6 alkyl), SO 2 NR 4 R 5 where R 4 and R 5 are as defined in relation to formula (Ii), preferably halogen, Ci -6 alkyl or Ci -6 alkoxy, more preferably halogen, especially fluorine, chlorine and bromine.
  • R 1 is phenyl, preferably it is mono- or di-substituted, more preferably monosubstituted, especially at the 3-position of the phenyl group.
  • R 2 is NR 6 R 7 where R 6 and R 7 are as hereinbefore defined.
  • one of R 6 and R 7 is hydrogen and the other is selected from Ci -6 alkyl, (CH 2 ) 0-3 C 3 . 7 cycloalkyl or (CH 2 ) 0-3 ⁇ R 9 , especially (CH 2 )o- 3 ⁇ R 9 .
  • R 9 is selected from hydrogen and Ci -4 alkyl, more preferably hydrogen.
  • NR 6 R 7 may be NH(CH 2 ) 2 OH.
  • R 2 is as defined in relation to formula (I), and
  • R 1 is phenyl substituted by bromine and/or CO 2 H, optionally further substituted by halogen, hydroxy, C 2 - 6 alkyl, Ci -6 alkoxy or CH 2 CO 2 H.
  • R 1 is as defined in relation to formula (I)
  • R 2 is C 3-8 cycloalkyl, (CH 2 ) 1-6 OH, C 2-8 alkoxy, phenyl,
  • R 2 is as defined in relation to formula (I), and R 1 is C 3-8 alkyl substituted by CO 2 H, C(O)NHCi -4 alkyl, C(O)NHS(O) 2 (Ci -6 alkyl),
  • alkyl or "alkoxy" as a group or part of a group means that the group is straight or branched.
  • suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl.
  • suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy.
  • the cycloalkyl groups referred to herein may represent, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
  • alkenyl and alkynyl as a group or part of a group means that the group is straight or branched.
  • suitable alkenyl groups include vinyl and allyl.
  • Suitable alkynyl groups are ethynyl and propargyl.
  • halogen means fluorine, chlorine, bromine and iodine.
  • aryl as a group or part of a group means a carbocyclic aromatic ring.
  • suitable aryl groups include phenyl and naphthyl.
  • heteroaryl as a group or part of a group means a 5- to 10-membered heteroaromatic ring system containing 1 to 4 heteroatoms selected from N, O and S.
  • groups include pyrrolyl, furanyl, thienyl, pyridyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazolyl, indolyl, benzimidazolyl, benzothienyl and quinolinyl.
  • Het as a group or part of a group means a heteroaliphatic ring of 4 to 7 ring atoms, which ring may contain 1, 2 or 3 heteroatoms selected from N, O or S or a group S(O), S(O) 2 , NH orNCi_ 4 alkyl.
  • substituents may be present.
  • Optional substituents may be attached to the compounds or groups which they substitute in a variety of ways, either directly or through a connecting group of which the following are examples: amine, amide, ester, ether, thioether, sulfonamide, sulfamide, sulfoxide, urea, thiourea and urethane.
  • an optional substituent may itself be substituted by another substituent, the latter being connected directly to the former or through a connecting group such as those exemplified above.
  • the salts of the compounds of formula (I) will be non-toxic pharmaceutically acceptable salts.
  • Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulfonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulfuric acid.
  • a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulfonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulfuric acid.
  • Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety.
  • suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.
  • the salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.
  • the present invention includes within its scope prodrugs of the compounds of formula (I) above.
  • prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible in vivo into the required compound of formula (I).
  • Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. ⁇ . Bundgaard, Elsevier, 1985.
  • a prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug” or “parent molecule”) that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule.
  • the transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulfate ester, or reduction or oxidation of a susceptible functionality.
  • the present invention includes within its scope solvates of the compounds of formula (I) and salts thereof, for example, hydrates.
  • the present invention also includes within its scope any enantiomers, diastereomers, geometric isomers and tautomers of the compounds of formula (I). It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the invention.
  • a method of inhibiting hepatitis C virus polymerase and/or of treating or preventing an illness due to hepatitis C virus the method involving administering to a human or animal (preferably mammalian) subject suffering from the condition a therapeutically or prophylactically effective amount of the pharmaceutical composition described above or of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof.
  • Effective amount means an amount sufficient to cause a benefit to the subject or at least to cause a change in the subject's condition.
  • a compound of formula (I), or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, in combination with one or more other agents for the treatment of viral infections such as an antiviral agent, and/or an immunomodulatory agent such as ⁇ -, ⁇ - or ⁇ -interferon, particularly ⁇ -interferon.
  • Suitable antiviral agents include ribavirin and inhibitors of hepatitis C virus (HCV) polymerase, such as inhibitors of metalloprotease (NS2-3), serine protease (NS3), helicase (NS3) and RNA-dependent RNA polymerase (NS5B).
  • a further aspect of the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (Ic) or (Id) as defined above or a compound selected from Group (II) as defined above, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
  • the composition may be in any suitable form, depending on the intended method of administration. It may for example be in the form of a tablet, capsule or liquid for oral administration, or of a solution or suspension for administration parenterally.
  • the composition may be prepared by admixing at least one active ingredient, or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable adjuvants, diluents or carriers and/or with one or more other therapeutically or prophylactically active agents.
  • a further aspect of the invention provides a compound of formula (Ic) or (Id) as defined above or a compound selected from Group (II) as defined above, or a pharmaceutically acceptable salt thereof for use in therapy.
  • a further aspect of the invention provides a compound of formula (Ic) or (Id) as defined above or a compound selected from Group (II) as defined above, or a pharmaceutically acceptable salt thereof.
  • the dosage rate at which the compound is administered will depend on a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age of the patient, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition and the host undergoing therapy.
  • suitable dosage levels may be of the order of 0.02 to 5 or 10 g per day, with oral dosages two to five times higher.
  • administration of from 10 to 50 mg of the compound per kg of body weight from one to three times per day may be in order. Appropriate values are selectable by routine testing.
  • the compound may be administered alone or in combination with other treatments, either simultaneously or sequentially.
  • it may be administered in combination with effective amounts of antiviral agents, immunomodulators, anti-infectives or vaccines known to those of ordinary skill in the art. It may be administered by any suitable route, including orally, intravenously, cutaneously and subcutaneously. It may be administered directly to a suitable site or in a manner in which it targets a particular site, such as a certain type of cell. Suitable targeting methods are already known.
  • compounds of formula (I) may be prepared by the reaction of a compound of formula (II) with a compound of formula (III):
  • R 1 , R 2 , A, B and n are as defined for formula (I).
  • the reaction is conveniently performed in the presence of a suitable solvent, such as NMP, ethanol or DMF, at a raised temperature, such as the reflux temperature of the solvent, and optionally under microwave irradiation.
  • a suitable solvent such as NMP, ethanol or DMF
  • R 1 , R 2 , A and B are as defined for formula (I), and L is a suitable leaving group such as chlorine, bromine or nitro.
  • the reaction is conveniently performed in the presence of a suitable solvent, such as NMP, at a raised temperature, optionally under microwave irradiation.
  • the compounds of formula (I) may be prepared by the reaction of the compound of formula (IV) with a compound of formula (VI): R 2 — B(OH) 2 (VI)
  • R 2 is as defined for formula (I).
  • the reaction is conveniently performed in the presence of a suitable catalyst, such as palladium triphenylphosphine, in a suitable solvent, such as a dimethyl ether/ethanol mixture, at raised temperature.
  • a suitable catalyst such as palladium triphenylphosphine
  • the starting material of formulae (II), (III), (IV) and (V) may be prepared by methods analogous to those described in the accompanying Examples, or by standard methods well known from the art.
  • a suitable reducing agent such as sodium borohydride
  • 1,8-naphthalimides were prepared by condensation reaction of naphthalic anhydrides with primary amines under microwave irradiation.
  • the 6-amino analogues were synthesised by treatment of 6-bromo- 1,8-naphthalimides with primary or secondary amines under microwave irradiation.
  • General method (A) is illustrated by Example 1 below.
  • the desired product can be separated therefrom at an appropriate stage by conventional methods such as preparative HPLC; or column chromatography utilising, for example, silica and/or alumina in conjunction with an appropriate solvent system.
  • any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T. W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 3rd edition, 1999.
  • the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
  • the following Examples are illustrative of the invention.
  • the compounds of the invention were tested for inhibitory activity against the HCV RNA dependent RNA polymerase (NS5B) in an enzyme inhibition assay (example i)).
  • the compounds have IC50's below 30 ⁇ M in the enzyme assay.
  • the HCV-BK cDNA sequence coding for the NS5B protein lacking of the 21 C-terminal residues (residues 1-570) was cloned in the pT7.7 vector downstream of the T7 promoter and in frame with the first ATG of the gene 10 protein of the T7 phage.
  • a C-terminal HisTag was added to simplify purification procedure.
  • Expression in E.coli BL21(DE3) was performed as described (Tomei et al., JGV (2000), 81, 759). Bacteria were grown at 37°C in standard LB medium up to an absorbance of 0.8 at 600 nm. The temperature of the culture was then lowered to 18°C and expression induced with 0.4 mM IPTG for further 23 hrs.
  • Lysis buffer contained 10 mM Tris [pH 8.0], 1 mM EDTA, 0.5 M NaCl, 50% glycerol, 10 mM ⁇ -mercaptoethanol, 0.1% n-octyl- ⁇ -D- glucopyranoside (Inalco; n-OG), CompleteTM protease inhibitor cocktail (Roche).
  • the extract was incubated with 0.5 units/ml of DNaseI for 30 min.
  • the insoluble material was pelletted by centrifugation for 60 min at 15,000 rpm in a Sorvall SS34 rotor.
  • the clarified supernatant was incubated batchwise for 45 min with 50 ml/liter of culture of DEAE-Sepharose FF resin equilibrated in lysis buffer lacking glycerol.
  • the flow-through from the DEAE-Sepharose was diluted to 0.3 M NaCl and loaded on a Ni-NTA Superflow column (Qiagen; 3 ml/liter of culture) equilibrated with A buffer + 10 mM Imidazole (A buffer: 10 mM Tris [pH 8.0], 20% glycerol, 0.3 M NaCl, 0.1% n-OG, 10 mM ⁇ -mercaptoethanol) and eluted with a 50 to 500 mM imidazole gradient in A buffer.
  • a buffer 10 mM Tris [pH 8.0], 20% glycerol, 0.3 M NaCl, 0.1% n-OG, 10 mM ⁇ -mercaptoethanol
  • Peak fraction were collected, dialysed vs D buffer (10 mM Hepes [pH 8.0], 20% glycerol, 0.2% n-OG, 1 mM EDTA, 5 mM DTT) containing 0.15 M NaCl and loaded on HiTrap Heparin column (Amersham) equilibrated with D buffer and eluted with a 0.15 to 0.8M NaCl gradient in D buffer.
  • the protein was stored in aliquots in liquid nitrogen.
  • the purified enzyme was shown to possess in vitro RNA polymerase activity using RNA as template according to a description in Journal of General Virology 81:759-767 (2000).
  • the reference describes a polymerisation assay using poly(A) and oligo(U) as a template/primer. Incorporation of tritiated UTP is quantified by measuring acid-insoluble radioactivity.
  • the present inventors have employed this assay to screen the various compounds described above as inhibitors of HCV RdRp.
  • Incorporation of radioactive UMP was measured as follows. The standard reaction (50 ⁇ l) was carried out in a buffer containing 20 mM Tris/HCl pH 7.5, 5 mM MgCl 2 , 1 mM DTT, 10 mM NaCl, 0.01% Triton X-100, 1 ⁇ Ci [ 3 H]-UTP (40 Ci/mmol, NEN), 10 ⁇ M UTP and 10 ⁇ g/ml poly(A) /Oligo(U)i 2 (1 ⁇ g/ml, Genset) as a template/primer. The final NS5B ⁇ C21 enzyme concentration was 5 nM.
  • AU solvents were obtained from commercial sources (Fluka, puriss.) and were used without further purification. With the exception of routine deprotection and coupling steps, reactions were carried out under an atmosphere of nitrogen in oven dried (110 °C) glassware. Organic extracts were dried over sodium sulfate, and were concentrated (after filtration of the drying agent) on rotary evaporators operating under reduced pressure. Flash chromatography was carried out on silica gel following published procedure (W.C. Still et al., J. Org. Chem. 1978, 43, 2923) or on semi-automated flash chromatography systems utilising pre-packed columns.
  • Reagents were usually obtained directly from commercial suppliers (and used as supplied) but a limited number of compounds from in-house corporate collections were utilised. In the latter case the reagents are readily accessible using routine synthetic steps that are either reported in the scientific literature or are known to those skilled in the art.
  • Mass spectral (MS) data were obtained on a Perkin Elmer API 100 operating in negative (ES " ) or positive (ES + ) ionization mode and results are reported as the ratio of mass over charge (m/z) for the parent ion only.
  • Preparative scale HPLC separations were carried out on a Waters Delta Prep 4000 separation module, equipped with a Waters 486 absorption detector or on a Gilson preparative system. In all cases compounds were eluted with linear gradients of water and acetonitrile both containing 0.1% TFA using flow rates between 15 and 25 mL/min.
  • Example 1 lH-benz[cfe]isoquinoline-l,3(2H)-dione, 2-(3-bromophenyl)-6-[(2-hydroxyethyl)amino]
  • Step 1 6-bromo-2-(3-bromophenyiy lH-benzo[ ⁇ fe]isoquinoline- 1 ,3(2H)-dione
  • Step 2 2-(3-bromophenyl)-6-[(2-hvdroxyethyl)aminol- lH-benz[ ⁇ felisoquinoline-1.3(2H)-dione
  • Example 2 2-(3-chlorophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione
  • a solution (0.09 M) of 4-bromo-l,8-naphthalic anhydride in EtOH was treated with 3-chloroaniline (1.5 eq.).
  • the reaction mixture was heated to reflux for 15 h.
  • reaction mixture was diluted with MeC ⁇ /DMSO (3:1) and it was purified by RP-HPLC (Conditions: Waters X-TERRA MS C18, 5 micron, 19 x 150 mm; flow: 20 mL/min; Gradient: A: H 2 O + 0.1% TFA; B: MeCN + 0.1% TFA; 99% A isocratic for 2 min, linear to 1% A in 10 min, 1% A isocratic for 5 min) to afford the title compound (20%) as a solid.
  • Step 2 2-butyl-6-[(2-hvdroxyethyl)aminol-lH-benzo[(Je1isoquinoline-l,3(2H)-dione
  • a solution (0.15 M) of 6-bromo-2-butyl-lH-benzo[cfe]isoquinoline-l,3(2H)-dione (from Step 1) in NMP was treated with 2-aminoethanol (1.2 eq.).
  • the reaction mixture was heated at 200°C under microwave irradiation for 30 min. After cooling down, the reaction mixture was diluted with EtOAc and water was added. The organic layer was separated and the aqueous layer was extracted with EtOAc.
  • Example 4 2-(3-bromophenyl)-6-[(2-hydroxyethyl)thio]-lH-benzo[cfe]isoquinoline-l,3(2H)-dione
  • a solution (1.0 M) of 6-[(2-hydroxyethyl)thio]-lH, 3H-benzo[cfe]isochromene-l,3-dione in NMP was treated with 3-bromoaniline (1.5 eq.).
  • the reaction mixture was heated at 200°C under microwave irradiation for 30 min. Then more 3-bromoaniline (0.75 eq) was added, and the reaction was heated under microwave irradiation for another 15 min. After cooling down, water and EtOAc were added.
  • Step 1 2-(3-chlorophenyl)-6-[(lJD-3-hvdroxyprop-l-en-l-yl1-lH-benzo[(Je1isoquinoline-1.3(2H)-dione
  • Step 2 2-(3-chlorophenyl)-6-(3-hvdroxypropyl)- lH-benzo[ ⁇ fe1isoquinoline- 1 ,3(2H)-dione
  • a solution (0.1 M) of 2-(3-chlorophenyl)-6-[(l£)-3-hydroxyprop-l-en-l-yl]-lH-benzo[cfe]isoquinoline- l,3(2H)-dione (from step 1) in MeO ⁇ /EtOAc (1:1) was treated with ZnBr 2 (0.2 eq.), 10% Pd on carbon (50% w/w) and stirred under H 2 (g) for 12 h.
  • the catalyst was then deactivate by bubbling N 2 for 10 min, filtered off and washed with hot MeOH and EtOAc.
  • the solution was evaporated to give a residue that was purified by RP-HPLC (Conditions: Waters Symmetry C 18, 5 micron, 19x300 mm; flow: 20 mL/min; Gradient: A: H 2 O + 0.1 %TFA; B: MeCN + 0.1% TFA; 60 % A isocratic for 3 min, linear to 10 % A in 23 min, 10 % A isocratic for 2 min) to afford the title compound (6% over two steps) as a solid.
  • Example 7 2-(3-chlorophenyl)-6-(lH-pyrazol-3-yl)-lH-benzo[cfe]isoquinoline-l,3(2H)-dione
  • a solution (0.1 M) of 6-bromo-2-(3-chlorophenyl)-lH-benzo[cfe]isoquinoline-l,3(2H)-dione (prepared as in Example 2) in DME/EtO ⁇ (2.6/1) was treated with lH-pyrazol-3-yl boronic acid (1.2 eq.), aqueous Na 2 CO 3 (2M solution) and Pd(PPh 3 ) 4 (0.1 eq.). The reaction mixture was heated at 80°C for 2 h.
  • Step 1 l,3-dioxo-lH,3H-benzo[(Je1isochromene-6-carboxylic acid
  • Step 2 3-[6-[(benzylamino)carbonyl1-l,3-dioxo-lH-benzo[de1isoquinolin-2(3H)-yllhexanoic acid
  • a solution (0.4 M) of l,3-dioxo-lH,3H-benzo[cfe]isochromene-6-carboxylic acid (from step 1) in CH 2 Cl 2 was treated with DMF (0.05 eq.) and cooled to 0 0 C.
  • Oxalyl chloride (2M solution in CH 2 Cl 2 , 2.0 eq.) was added and the reaction mixture was stirred at 0°C for 1 h., then at 25°C for 1 h.
  • Step 1 feft-butyl 6-bromo-1.3-dioxo-lH-berizo[ ⁇ fe]isoquinoline-2(3H)-carboxylate
  • a solution (0.9 M) of 6-bromo-lH,3H-benzo[cfe]isochromene-l,3-dione in EtOH and ammonia (32% aqueous solution, 1 eq.) were mixed in an Ace tube. The tube was well closed and heated at 80°C for 3 h. After cooling down, a precipitate was formed. The precipitate was isolated by filtration and washed with small portions of EtOH. The resulting solid was dissolved in dioxane.
  • Step 2 6- ⁇ [2-(benzyloxy)ethyl]amino
  • a solution (0.5 M) of tert-butyl 6-bromo-l,3-dioxo-lH-benzo[cfe]isoquinoline-2(3H)-carboxylate (from step 1) and 2-(benzyloxy)ethanamine (3 eq.) in NMP (0.5 M) was heated at 180°C under microwave irradiation for 30 min. Then, the reaction was treated with water and kept at 4°C overnight. The resulting precipitate was isolated by filtration giving the title compound (70%) as a solid; m/z 347 (M+ ⁇ ) + .
  • Step 3 6-[(2-hydroxyethyl)amino]-2-[(5-methylisoxazol-3-yl)methyl]- lH-benzo[ ⁇ fe]isoquinoline-
  • Example 10 d.y ⁇ -IP-CS-chloropheny ⁇ -l ⁇ -dioxo ⁇ -dihydro-lH-benzotfifelisoquinolin- ⁇ - yl]amino ⁇ cyclohexanecarboxylic acid
  • Step 1 methyl cis-4- ⁇ [2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[(Je1isoquinolin-6- yl]amino
  • Step 2 cis-4- ⁇ [2-(3-chlorophenvD- 1 ,3-dioxo-2,3-dihydro- lH-benzo[ ⁇ fe1isoquinolin-6- yl]amino

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of naphthalimide compounds of formula (I), wherein A, B, R1, R2, n and Ra are defined herein, and pharmaceutically acceptable salts thereof, for the treatment or prevention of infection by hepatitis C virus.

Description

Naphthalimide derivatives as antiviral agents
This invention relates to compounds which can act as inhibitors of viral polymerases, especially the hepatitis C virus (HCV) polymerase, to uses of such compounds in the treatment and prevention of infection by hepatitis C virus, and to their preparation.
The hepatitis C virus (HCV) is the major causative agent of parenterally-transmitted and sporadic non-A, non-B hepatitis (NANB-H). Some 1% of the human population of the planet is believed to be affected. Infection by the virus can result in chronic hepatitis and cirrhosis of the liver, and may lead to hepatocellular carcinoma. Currently no vaccine nor established therapy exists, although partial success has been achieved in a minority of cases by treatment with recombinant interferon-α, either alone or in combination with ribavirin. There is therefore a pressing need for new and broadly-effective therapeutics.
Several virally-encoded enzymes are putative targets for therapeutic intervention, including a metalloprotease (NS2-3), a serine protease (NS3), a helicase (NS3), and an RNA-dependent RNA polymerase (NS5B). Of these, the polymerase plays an essential role in replication of the virus and is therefore an important target in the fight against hepatitis C.
Certain naphthalimide derivatives have been disclosed in the art but none are disclosed as being useful as inhibitors of hepatitis C virus (HCV) polymerase.
Published International application WO 00/32577 (Merck Patent GmbH) discloses the compounds of formula (A):
Figure imgf000002_0001
where R, R1 and R2 are as defined therein, as glycoprotein IbIX antagonists.
Published International application WO 00/01672 (Taiho Pharmaceutical Co., Ltd.) discloses the compounds of formula (B):
Figure imgf000002_0002
where X1, Y, A1, R1, R2 and e are as defined therein. These compounds are disclosed as being useful as antitumour agents. 4-alkylamino-N-alkylnaphthalic-l,8-imides are also disclosed in, for instance, Alexiou et al. J. Chem. Research (S), 2000, 208-210; Ghorbanian et al. J. Chem. Technol. BiotechnoL, 75:1127-1134 (2000); and Qian et al. Dyes and Pigments, 11(1989), 13-20.
However none of these disclosures relate to the treatment of hepatitis C virus infections.
It has now surprisingly been found that certain naphthalimide derivatives, including certain of the known compounds referred to above, act as inhibitors of the hepatitis C virus (HCV) polymerase enzyme.
Thus, in one aspect, there is provided the use of a compound of formula (I):
Figure imgf000003_0001
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein
A and B are each independently CH2, C=O or C=S, with the proviso that A and B are not both CH2;
R1 is Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, (CH2)0-3C3-7cycloalkyl, (CH2)0-3Het, (CH2)0-3aryl or (CH2)0-3heteroaryl, optionally substituted by halogen, hydroxy, Ci-6alkyl, Ci-6alkoxy, C2-6alkenyl, CN, (CH2)0-3θ(CH2)o-3aryl, S(Ci-6alkyl), S(O)(Ci-6alkyl), S(O)2(Ci-6alkyl), S-heteroaryl, S(O)heteroaryl, S(O)2heteroaryl, S-aryl, S(O)aryl, S(O)2aryl, SO2NR4R5, CO2R4, CONR4R5, NR4COR5, NR4SO2R5 or NR4CONR5 where said Ci-6alkyl, (CH2)0-3Het, (CH2)0-3aryl and (CH2)0-3heteroaryl groups, either by themselves or as part of other substituents, may optionally be substituted by 1 to 8 halogen atoms, and where said (CH2)0-3Het, (CH2)0-3aryl and (CH2)0-3heteroaryl groups may optionally be further substituted with one or two groups selected from hydroxy, Ci-6alkoxy, Ci-6alkyl, (CH2)0-3CO2H, (CH2)0-3CO2Ci.6alkyl and C(O)NR24R25, and where said (CH2)0-3aryl group may be fused to C3-7cycloalkyl;
R4, R5 and R21 are each independently selected from hydrogen, Ci-6alkyl, (CH2)0-3Het, (CH2)o-3aryl, (CH2)0-3heteroaryl and SO2(Ci-6alkyl), optionally substituted by 1 to 5 halogen atoms and/or 1 or 2 groups selected from hydroxy, Ci-6alkyl, NH2 and Ci-6alkoxy;
R2 is halogen, hydroxy, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, (CH2)0-3C3-8cycloalkyl, (CH2)o-3aryl, CN, NO2, NR6R7, OR8, C(O)C i-6alkyl, CO2H, CO2R8, CONR8R20, NR21COR8, NR21SO2R8, NR8CONR20, SR8, SOR8, SO2R8 or SO2NR8R20, where said Ci-6alkyl, C2-6alkenyl, Ci-6alkoxy and aryl groups are optionally substituted by 1 or 2 groups selected from halogen, hydroxy, Ci-6alkyl, Ci-6alkoxy, NH2, SO2NR6R7, CO2R6 and CONR6R7;
R6 and R7 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, (CH2)o-3C3-7cycloalkyl, (CH2)0-3Het, (CH2)0-3aryl, (CH2)0-3heteroaryl, (CH2)0-3OR9, (CH2)0-3SR9, (CH2)O-3NR10R11, -C(CH2OH)3, COR22, C(O)C(O)OCi-6alkyl, CO2R22, CONR22R23, SO2R22 and SO2NR22R23, where said Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, cycloalkyl, Het, aryl and heteroaryl groups are optionally substituted by 1 or 2 groups selected from halogen, hydroxy, Ci-6alkyl, CF3, NH2, N(Ci-6alkyl)2, SO2aryl, SO2NR18R19, (CH2)0-3aryl, (CH2)0-3heteroaryl, C(O)C i-6alkyl, C(O)(CH2)0-3aryl, (CH2)O-3CO2R18, (CH=CH)CO2R18, CONR18R19 and O(CH2)0-3aryl, which optional aryl substituents are further optionally substituted by CO2H or Het;
R18 and R19 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, (CH2)0-3C3-7cycloalkyl, (CH2)0-3Het, (CH2)0-3aryl, (CH2)0-3heteroaryl, (CH2)0-3OR9, (CH2)0-3SR9, (CH2)O-3NR10R11, -C(CH2OH)3, where said Ci-6alkyl, C2-6alkenyl and Ci-6alkoxy groups are optionally substituted by halogen or hydroxy;
R9, R10 and R11 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, C(O)Ci-6alkyl and aryl; or R6, R7 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, which ring optionally contains 1, 2 or 3 additional heteroatoms selected from O and S or a group S(O), S(O)2 or NR12, where R12 is hydrogen, Ci-6alkyl, C2-6alkenyl or aryl, and which ring is optionally substituted by halogen, hydroxy, Ci-6alkyl, C2-6alkenyl, Ci-6alkoxy, oxo, SO2NR18R19, COR18, CO2R18 or CONR18R19 , and which ring is optionally bridged by -CH2- or -CH2CH2-;
R8, R20, R22 and R23 are each independently selected from hydrogen, Ci-6alkyl, (CH2)i-3OR13, (CH2)1-3NR14R15, (CH2)o-3aryl and (CH2)0-3heteroaryl;
R13, R14 and R15 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, aryl, C(O)R16 and C(O)OR17 ;
R16, R17 and R24 are independently selected from hydrogen, Ci-6alkyl and aryl;
R25 is hydrogen, Ci-6alkyl, (CH2)i-3CO2H, (CH2)0-3C3-8cycloalkyl, (CH2)0-3phenyl or SO2(Ci-6alkyl), where C3-8cycloalkyl and phenyl are optionally substituted by 1 to 3 groups selected from halogen, hydroxy or CO2H; n is O or 1 or 2, and when n is 2, the R2 groups may be the same or different;
Ra is hydrogen, o orr R R22 a anndd R Raa a arree joined to form a 5- to 8-membered carbocyclic ring.
In one embodiment of the present invention, there is provided the use of a compound of formula
(Ii):
(Ii)
Figure imgf000004_0001
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein
A and B are each independently CH2, C=O or C=S, with the proviso that A and B are not both CH2;
R1 is Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, (CH2)0-3C3-7cycloalkyl, (CH2)0-3Het, (CH2)0-3aryl or (CH2)0-3heteroaryl, optionally substituted by halogen, hydroxy, Ci-6alkyl, Ci-6alkoxy, C2-6alkenyl, CN, S(Ci-6alkyl), S(O)(Ci-6alkyl), S(O)2(Ci-6alkyl), S-heteroaryl, S(O)heteroaryl, S(O)2heteroaryl, S-aryl, S(O)aryl, S(O)2aryl, SO2NR4R5, CO2R4, CONR4R5, NR4COR5, NR4SO2R5 or NR4CONR5 where said Ci-6alkyl and (CH2)0-3aryl groups, either by themselves or as part of other substituents, may optionally be substituted by 1 to 8 halogen atoms;
R4, R5 and R21 are each independently selected from hydrogen, Ci-6alkyl, (CH2)0-3Het, (CH2)0-3aryl and (CH2)0-3heteroaryl;
R2 is halogen, hydroxy, Ci-6alkyl, C2-6alkenyl, Ci-6alkoxy, CN, NO2, NR6R7, OR8, CO2H, CO2R8, CONR8R20, NR21COR8, NR21SO2R8, NR8CONR20, SR8, SOR8, SO2R8 or SO2NR8R20, where said Ci-6alkyl, C2-6alkenyl and Ci-6alkoxy groups are optionally substituted by halogen, hydroxyl, SO2NR6R7, CO2R6 or CONR6R7;
R6 and R7 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, (CH2)O-3C3-7CyClOaIlCyI, (CH2)0-3Het, (CH2)0-3aryl, (CH2)0-3heteroaryl, (CH2)0-3OR9, (CH2)0-3SR9, (CH2)O-3NR10R11, -C(CH2OH)3, COR22, CO2R22, CONR22R23, SO2R22 and SO2NR22R23, where said Ci-6alkyl, C2-6alkenyl, cycloalkyl, Het, aryl and heteroaryl groups are optionally substituted by halogen, hydroxy, SO2NR18R19, CO2R18 or CONR18R19;
R18 and R19 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, (CH2)o-3C3-7cycloalkyl, (CH2)0-3Het, (CH2)0-3aryl, (CH2)0-3heteroaryl, (CH2)0-3OR9, (CH2)0-3SR9, (CH2)O-3NR10R11, -C(CH2OH)3, where said Ci-6alkyl, C2-6alkenyl and Ci-6alkoxy groups are optionally substituted by halogen or hydroxy;
R9, R10 and R11 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, C(O)Ci-6alkyl and aryl; or R6, R7 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, which ring optionally contains 1, 2 or 3 additional heteroatoms selected from O and S or a group S(O), S(O)2 or NR12, where R12 is hydrogen, Ci-6alkyl, C2-6alkenyl or aryl, and which ring is optionally substituted by halogen, hydroxy, Ci-6alkyl, C2-6alkenyl or Ci-6alkoxy, carboxyl, SO2NR18R19, COR18, CO2R18 or CONR18R19;
R8, R20, R22 and R23 are each independently selected from Ci-6alkyl, (CH2)i-3OR13, (CH2)1-3NR14R15, (CH2)o-3aryl and (CH2)0-3heteroaryl;
R13, R14 and R15 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, aryl, C(O)R16 and C(O)OR17 ;
R16 and R17 are independently selected from hydrogen, Ci-6alkyl and aryl; n is O or 1.
In one embodiment of the present invention, one of A or B is C=O and the other is CH2 or C=O, preferably A is C=O and B is CH2 or C=O, more preferably A and B are C=O.
In another embodiment, R1 is (CH2)0-3aryl, preferably (CH2)0-3phenyl, more preferably phenyl or benzyl, most preferably phenyl, optionally substituted by halogen, hydroxy, Ci-6alkyl, Ci-6alkoxy, C2-6alkenyl, CN, S(CX-6 alkyl), S(O)(Ci-6alkyl), S(O)2(Ci-6alkyl), SO2NR4R5 where R4 and R5 are as hereinbefore defined, preferably halogen, Ci-6alkyl or Ci-6alkoxy, more preferably, fluorine, chlorine, bromine, most preferably bromine.
When R1 is substituted, it is preferably mono- or di-substituted, more preferably mono- substituted.
When R1 is phenyl and substituted, preferably it is substituted at the 3-position of the phenyl group, especially when it is mono-substituted.
In another embodiment, R2 is NR6R7 where R6 and R7 are as hereinbefore defined. Preferably, R6 and R7 are independently selected from hydrogen, Ci-6alkyl, (CH2)0-3C3.7cycloalkyl, (CH2)0-3θR9 where R9 is as hereinbefore defined. More preferably, one of R6 and R7 is hydrogen and the other is selected from Ci-6alkyl, (CH2)o-3C3-7cycloalkyl or (CH2V3OR9, especially (CH2)2OR9. Preferably, R9 is selected from hydrogen, C^alkyl and aryl, more preferably hydrogen.
In another embodiment, when n is 1, preferably the R2 group is at the 4-position of the naphthalimide moiety.
In a further embodiment of the present invention, there is provided the use of a compound of formula (Ia):
Figure imgf000006_0001
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein R1 and R2 are as defined in relation to formula (Ii).
Preferably, R1 is (CH2)0-3aryl, more preferably phenyl, optionally substituted by halogen, hydroxy, Ci-6alkyl, Ci-6alkoxy, C2-6alkenyl, CN, S(Ci-6alkyl), S(O)(Ci-6alkyl), S(O)2(Ci-6alkyl), SO2NR4R5 where R4 and R5 are as defined in relation to formula (Ii), preferably halogen, Ci-6alkyl or Ci-6alkoxy, more preferably halogen, especially fluorine, chlorine and bromine.
When R1 is phenyl, preferably it is mono- or di-substituted, more preferably monosubstituted, especially at the 3-position of the phenyl group.
Preferably, R2 is NR6R7 where R6 and R7 are as hereinbefore defined. Preferably, one of R6 and R7 is hydrogen and the other is selected from Ci-6alkyl, (CH2)0-3C3.7cycloalkyl or (CH2)0-3θR9, especially (CH2)o-3θR9. Preferably, R9 is selected from hydrogen and Ci-4alkyl, more preferably hydrogen. In particular, NR6R7 may be NH(CH2)2OH.
In a further embodiment, there is provided the use of a compound of formula (Ib):
Figure imgf000007_0001
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein
R2 is as defined in relation to formula (I), and
R1 is phenyl substituted by bromine and/or CO2H, optionally further substituted by halogen, hydroxy, C2-6alkyl, Ci-6alkoxy or CH2CO2H.
In a further embodiment, there is provided the use of a compound of formula (Ic):
Figure imgf000007_0002
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein R1 is as defined in relation to formula (I), and R2 is C3-8cycloalkyl, (CH2)1-6OH, C2-8alkoxy, phenyl,
NH(CH2)0-3Het substituted by C(O)(CH2)0-3aryl, C(O)(Ci-6alkyl), C(O)C3-8cycloalkyl, SO2aryl, (CH2)i-3aryl (optionally substituted by CO2Ci-6alkyl or (CH2)0-3CO2H), (CH2)i-3heteroaryl or (CH2)i-3C(O)OCi-6alkyl, NH(CH2)0-3C3.8cycloalkyl substituted by CO2H or CO2(Ci-6alkyl), NHC(O)Ci-6alkyl, NHC(0)(CH2)o-3aryl, NH(CH2)2O(CH2)1-3aryl, 3-oxo-2-azabicyclo[2.2.2]oct-2-yl, NH(CH2)o-3aryl substituted by CO2H, CO2Ci-6alkyl, Het or CH=CHC(O)OC i-6alkyl, CO2H, or
C(0)NH(CH2)o-3aryl, where phenyl is optionally substituted by 1 to 3 groups selected from halogen, Ci-6alkyl, NH2, Ci-6alkoxy or CO2H. In a further embodiment, there is provided the use of a compound of formula (Id):
Figure imgf000008_0001
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein R2 is as defined in relation to formula (I), and R1 is C3-8alkyl substituted by CO2H, C(O)NHCi-4alkyl, C(O)NHS(O)2(Ci-6alkyl),
C(O)NH(CH2)0-3heteroaryl, C(O)NH(CH2)0-3Het, C(O)NHCH(CH3)phenyl or 0(CH2)o-3aryl, (CH2)i-3C3-8cycloalkyl, (CH2)3aryl, (CH2)1-2Het, (CH2)3heteroaryl, phenyl substituted by SH, SCi-6alkyl or SO2C2-6alkyl, C(O)NH(CH2)1-3aryl, C(O)NH(CH2)1-3CO2H, or
C(O)NH(C3-8cycloalkyl) substituted by CO2H or C(O)NHSO2(C i-6alkyl), where the Het groups of (CH2)i-2Het and C(O)NH(CH2)0-3Het are optionally substituted by Ci-4alkyl, OH or NH2, and where the aryl group of C(O)NH(CH2)i-3aryl is optionally substituted by CO2H, halogen, Ci-4alkyl or
Figure imgf000008_0002
and where the heteroaryl group of C(O)NH(CH2)0-3heteroaryl is optionally substituted by Ci-4alkyl.
When any variable occurs more than one time in formula (I) or in any substituent, its definition on each occurrence is independent of its definition at every other occurrence.
As used herein, the term "alkyl" or "alkoxy" as a group or part of a group means that the group is straight or branched. Examples of suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy. The cycloalkyl groups referred to herein may represent, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
As used herein, the term "alkenyl" and "alkynyl" as a group or part of a group means that the group is straight or branched. Examples of suitable alkenyl groups include vinyl and allyl. Suitable alkynyl groups are ethynyl and propargyl.
When used herein, the term "halogen" means fluorine, chlorine, bromine and iodine.
When used herein, the term "aryl" as a group or part of a group means a carbocyclic aromatic ring. Examples of suitable aryl groups include phenyl and naphthyl.
When used herein, the term "heteroaryl" as a group or part of a group means a 5- to 10-membered heteroaromatic ring system containing 1 to 4 heteroatoms selected from N, O and S. Particular examples of such groups include pyrrolyl, furanyl, thienyl, pyridyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, oxadiazolyl, thiadiazolyl, triazinyl, tetrazolyl, indolyl, benzimidazolyl, benzothienyl and quinolinyl.
When used herein, the term "Het" as a group or part of a group means a heteroaliphatic ring of 4 to 7 ring atoms, which ring may contain 1, 2 or 3 heteroatoms selected from N, O or S or a group S(O), S(O)2, NH orNCi_4alkyl.
Where a compound or group is described as "optionally substituted", one or more substituents may be present. Optional substituents may be attached to the compounds or groups which they substitute in a variety of ways, either directly or through a connecting group of which the following are examples: amine, amide, ester, ether, thioether, sulfonamide, sulfamide, sulfoxide, urea, thiourea and urethane. As appropriate an optional substituent may itself be substituted by another substituent, the latter being connected directly to the former or through a connecting group such as those exemplified above.
Specific compounds within the scope of this invention include those compounds named in the Examples and Tables below and their pharmaceutically acceptable salts. Preferred compounds of the present invention are those of Group (II) as defined below:
Group (IT): lH-benz[fife]isoquinoline-l,3(2H)-dione, 2-(3-bromophenyl)-6-[(2-hydroxyethyl)amino],
2-(3-chlorophenyl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-butyl-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-[(2-hydroxyethyl)thio]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-7-[(2-hydroxyethyl)amino]-2,3-dihydro-lH-benzo[fife]isoquinolin-l-one,
2-(3-chlorophenyl)-6-(3-hydroxypropyl)-lΗ-benzo[cfe]isoquinoline-l,3(2Η)-dione,
2-(3-chlorophenyl)-6-(lH-pyrazol-3-yl)-lH-benzo[cfe]isoquinoline-l,3(2H)-dione,
3-[6-[(benzylamino)carbonyl]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]hexanoic acid,
6-[(2-hydroxyethyl)amino]-2-[(5-methylisoxazol-3-yl)methyl]-lH-benzo[fife]isoquinoline-l,3(2H)-dione, cis-4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid,
2-(3-bromophenyl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-[(2-methoxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-(propylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-[(3-hydroxypropyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
6-amino-2-(3-bromophenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-[(2-hydroxyethyl)thio]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-(methylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6- { [2-(dimethylamino)ethyl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-(isobutylamino)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-bromophenyl)-6-(ethylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
6-(benzylamino)-2-(3-bromophenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-[(2-phenylethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-[(2-phenoxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-bromophenyl)-6-[(2-hydroxyethyl)(methyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-[(tetrahydroftαran-2-ylmethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-(cyclopentylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-(cyclohexylamino)- lH-benzo[de]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-(isopropylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6- { [2-(methylthio)ethyl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-methoxy- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
N-(2- { [2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} ethyl)acetamide,
2-(3-bromophenyl)-6- { [2-(methylamino)ethyl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-(2-hydroxyethoxy)- lH-benzo[de]isoquinoline- 1 ,3(2H)-dione,
6-[(2-aminoethyl)amino]-2-(3-bromophenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-bromophenyl)-6-[(cyclopropylmethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-bromophenyl)-6-[(pyridin-2-ylmethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, benzyl (2- { [2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} ethyl)carbamate,
6-[(l-benzylpiperidin-4-yl)amino]-2-(3-bromophenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
4-( { [2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}methyl)benzoic acid, trans-4- { [2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid, cis-4- { [2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid,
4- { [2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}piperidinium trifluoroacetate,
6-[(2-hydroxyethyl)amino]-2-phenyl-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-benzyl-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-butyl-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-cyclohexyl-6-[(2-hydroxyethyl)amino]- lH-benzo[de]isoquinoline- 1 ,3(2H)-dione,
6-[(2-hydroxyethyl)amino]-2-isobutyl-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]benzonitrile,
6-[(2-hydroxyethyl)amino]-2-(3-methoxyphenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
6-[(2-hydroxyethyl)amino]-2-(3-methylphenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
6-[(2-hydroxyethyl)amino]-2-[3-(methylthio)phenyl]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(4-bromophenyl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione
6-[(2-hydroxyethyl)amino]-2-[3-(trifluoromethyl)phenyl]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-fluorophenyl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
6-[(2-hydroxyethyl)amino]-2-[3-(methylsulfonyl)phenyl]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(5-bromopyridin-3-yl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]benzenesulfonamide,
2-(2-bromophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3,5-dichlorophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(2,3-dichlorophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(2,5-dichlorophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-chloro-4-fluorophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-chloro-4-methoxyphenyl)-6-[(2-hydroxyethyl) amino]- lH-benzo[cfe]isoquinoline-l,3(2H)-dione,
6-[(2-aminoethyl)amino]-2-phenyl- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, methyl { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} (oxo)acetate,
6-[(l-benzoylpiperidin-4-yl)amino]-2-(3-chlorophenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
6-[(l-acetylpiperidin-4-yl)amino]-2-(3-chlorophenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-chlorophenyl)-6- { [ 1 -(cyclohexylcarbonyl)piperidin-4-yl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)- dione,
2-(3-chlorophenyl)-6- { [ 1 -(phenylsulfonyl)piperidin-4-yl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)- dione,
N-[2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]glycine,
4-( { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}methyl)cyclohexanecarboxylic acid,
2-(3-chlorophenyl)-5-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-[(4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}piperidin- 1 - yl)carbonyl]benzoic acid,
4-[(4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}piperidin- 1 - yl)carbonyl]benzoic acid,
N-[2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-5-yl]acetamide,
4-chloro-2-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]benzoic acid,
N-[2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]-2-phenylacetamide,
2-(3-chlorophenyl)-5-(methylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-5-(dimethylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-( { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-5-yl]amino}methyl)pyridinium trifluoroacetate, trans-A- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid,
2-(3-chlorophenyl)-6-(2-oxopyrrolidin-l-yl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
5- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}pentanoic acid, 1 -benzyl-4- { [2-(2-carboxy-5-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}piperidinium trifluoroacetate, (25)-2-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]pentanoic acid,
4- { [2-(3-carboxyphenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}piperidinium trifluoroacetate,
3-[6-[(l-acetylpiperidin-4-yl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-5-bromobenzoic acid,
1 -benzyl-4-( {2-[(l S)- 1 -carboxybutyl]- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl}amino)piperidinium trifluoroacetate, ethyl 2-(6-bromo- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl)- 1 ,3-thiazole-5-carboxylate,
6- { [2-(benzyloxy)ethyl]amino} -2-[(5-methylisoxazol-3-yl)methyl]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)- dione,
6-[(2-hydroxyethyl)amino]-2-[(5-methylisoxazol-3-yl)methyl]-lH-benzo[fife]isoquinoline-l,3(2H)-dione, 3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]benzoic acid, 4-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]benzoic acid, 2-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-4-methylpentanoic acid, methyl cis-4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylate,
2-(3-chlorophenyl)-6-(3-oxo-2-azabicyclo[2.2.2]oct-2-yl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione, 2-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]benzoic acid, cis-4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid, 4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 - methylpiperidinium trifluoroacetate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[de]isoquinolin-6-yl]amino} - 1 -(2- phenylethyl)piperidinium trifluoroacetate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 - propylpiperidinium trifluoroacetate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 -(1 ,3-thiazol-2- ylmethyl)piperidinium trifluoroacetate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 -[4-
(methoxycarbonyl)benzyl]piperidinium trifluoroacetate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 - isopropylpiperidinium trifluoroacetate, l-benzyl-4-({2-[3-bromo-5-(ethoxycarbonyl)phenyl]-l,3-dioxo-2,3-dihydro-lH-benzo[fife]isoquinolin-6- yl}amino)piperidinium trifluoroacetate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 -(2-ethoxy-2- oxoethyl)piperidinium trifluoroacetate, l-(4-carboxybenzyl)-4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}piperidinium trifluoroacetate,
6-anilino-2-(3-chlorophenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(4-methoxyphenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[cfe]isoquinolin-6-yl]benzoic acid,
4-[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[cfe]isoquinolin-6-yl]benzoic acid,
2-(3-chlorophenyl)-6-(3-fluoro-4-methoxyphenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(2-fluoro-4-methoxyphenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(4-fluoro-3-methylphenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(5-fluoro-2-methoxyphenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-[2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]- lH-pyrazol- 1 -ium trifluoroacetate,
2-(3-chlorophenyl)-6-(3-thienyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
4-[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[cfe]isoquinolin-6-yl]pyridinium trifluoroacetate,
2-(3-chlorophenyl)-6-(3-furyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[cfe]isoquinolin-6-yl]pyridinium trifluoroacetate,
2-(3-chlorophenyl)-6-pyrimidin-5-yl- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[fife]isoquinolin-6-yl]benzenaminium trifluoroacetate,
2-(3-chlorophenyl)-6-cyclohexyl- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, l-(carboxymethyl)-4-{[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[cfe]isoquinolin-6- yl]amino}piperidinium trifluoroacetate,
1 -benzyl-3- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}pyrrolidinium trifluoroacetate, methyl 4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}benzoate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}benzoic acid,
2-(3-chlorophenyl)-6-(pyridin-2-ylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(pyridin-3-ylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]hexanoic acid,
3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N,N- dimethylbenzamide,
3- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}benzoic acid,
2-(3-chlorophenyl)-6-[(4-morpholin-4-ylphenyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
6- { [3-(benzyloxy)phenyl]amino} -2-(3-chlorophenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(quinolin-3-ylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(isoquinolin-7-ylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, ethyl (2£)-3-(4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}phenyl)acrylate,
2-(3-chlorophenyl)-6- { [3-(trifluoromethyl)phenyl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
6-[(4-,yec-butylphenyl)amino]-2-(3-chlorophenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-chlorophenyl)-6- { [4-(trifluoromethyl)phenyl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N- methylbenzamide,
N- {3-bromo-5-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl]benzoyl} -β- alanine,
4-[({3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljbenzoyl} amino)methyl]benzoic acid, c/.y-4-({3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljbenzoyl} amino)cyclohexanecarboxylic acid,
3-({3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H))- yljbenzoyl} amino)cyclohexanecarboxylic acid,
3- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} -NN- dimethylbenzenaminium trifluoroacetate,
3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-
(methylsulfonyl)benzamide,
2-(6-anilino- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl)pentanoic acid, 4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} -2- methylquinolinium trifluoroacetate, ethyl 3-(6-anilino- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl)-5-chlorobenzoate,
3-(6-anilino- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl)-5-chlorobenzoic acid,
4- { [2-(3-carboxy-5-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 - isopropylpiperidinium trifluoroacetate,
4- { [2-(3-carboxy-5-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 -(2- phenylethyl)piperidinium trifluoroacetate,
4-[(4- { [2-(3-carboxy-5-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}piperidinium- 1 -yl)methyl]pyridinium bis(trifluoroacetate),
1 -benzyl-4-[(2- {3-bromo-5-[(methylamino)carbonyl]phenyl} - 1 ,3-dioxo-2,3-dihydro- IH- benzo[fife]isoquinolin-6-yl)amino]piperidinium trifluoroacetate,
6-amlino-2-butyl- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
4-[(2-butyl- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl)amino]- 1 -isopropylpiperidinium trifluoroacetate,
3-(6-anilino- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl)hexanoic acid,
4-( {2-[ 1 -(carboxymethyl)butyl]- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl} amino)- 1 - isopropylpiperidinium trifluoroacetate,
2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinoline-6-carboxylic acid,
2-[ 1 -(carboxymethyl)butyl]- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinoline-6-carboxylic acid,
3-[6-[(benzylamino)carbonyl]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]hexanoic acid,
2-(5-chloro-2-methoxyphenyl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-(6-anilino- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl)-N-(methylsulfonyl)hexanamide,
1 -isopropyl-4-( {3-[6-[( 1 -isopropylpiperidinium-4-yl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)- yljhexanoyl} amino)piperidinium bis(trifluoroacetate),
1 -isopropyl-4-[(2- { 1 -[2-(methylamino)-2-oxoethyl]butyl} - 1 ,3-dioxo-2,3-dihydro- IH- benzo[fife]isoquinolin-6-yl)amino]piperidinium trifluoroacetate,
2-(5-chloro-2-hydroxyphenyl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(2,3-dihydro-lh-inden-4-yl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-chloro-2-fluorophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-bromo-2-methylphenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
6-[(2-hydroxyethyl)amino]-2-(4-methylpyridin-2-yl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
3-( { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}methyl)benzoic acid,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-l,3,4-thiadiazol-2- ylhexanamide, 2- { 1 -[2-(3-amino- lH-pyrazol- 1 -yl)-2-oxoethyl]butyl} -6-[(2-hydroxyethyl)amino]- IH- benzo[fife]isoquinoline- 1 ,3(2H)-dione,
2-( {3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl]hexanoyl} amino)- 1 ,3- thiazol-3-ium trifluoroacetate,
3-[({3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanoyl} amino)methyl]pyridinium trifluoroacetate,
2-[({3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanoyl} amino)methyl]pyridinium trifluoroacetate,
4-[({3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanoyl} amino)methyl]pyridinium trifluoroacetate,
3-[2-({3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanoyl} amino)ethyl]pyridinium trifluoroacetate,
5-[2-({3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanoyl} amino)ethyl]- lH-imidazol-3-ium trifluoroacetate,
2-(3-chlorophenyl)-6-(3-hydroxypropyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
6-[(2-hydroxyethyl)amino]-2-(3-methylcyclohexyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
N-(2,6-difluorobenzyl)-3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)- yljhexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H))-yl]-N-[2-(lH-l,2,4-triazol-5- yl)ethyl]hexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-(2-pyridin-4- ylethyl)hexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-(lH-indol-6- ylmethyl)hexanamide,
N-benzyl-3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]hexanamide,
N-(2,6-dimethoxybenzyl)-3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanamide,
N-(2,6-difluorobenzyl)-3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)- yljhexanamide,
N-(2,6-difluorobenzyl)-3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)- yljhexanamide,
{3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]phenyl}acetic acid,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-[(lR)-l- phenylethyljhexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-[(lR)-l- phenylethyljhexanamide,
N-[(37?,47?)-4-hydroxy- 1 , 1 -dioxidotetrahydro-3-thienyl]-3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- IH- benzo[fife]isoquinolin-2(3H)-yl]hexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-[(l-methyl-lh-pyrazol-4- yl)methyl]hexanamide,
N-(2-chloro-6-methylbenzyl)-3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[fife]isoquinolin-2(3H)- yljhexanamide,
N-(2-fluorobenzyl)-3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[fife]isoquinolin-2(3H)- yljhexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-[(15)-l- phenylethyljhexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-[(15)-l- phenylethyljhexanamide,
2-butyl-6-(butylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-[({3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanoyl} amino)methyl]-5,7-dimethyl[ 1 ,2,4]triazolo[ 1 ,5-a]pyrimidin- 1 -ium trifluoroacetate,
1 -benzyl-4-( { 1 ,3-dioxo-2-[ 1 -(2-oxo-2- { [(75)- 1 -phenylethyljamino} ethyl)butyl]-2,3-dihydro- IH- benzo[cfe]isoquinolin-6-yl}amino)piperidinium trifluoroacetate,
1 -benzyl-4-( { 1 ,3-dioxo-2-[ 1 -(2-oxo-2- { [(75)- 1 -phenylethyljamino} ethyl)butyl]-2,3-dihydro- IH- benzo[cfe]isoquinolin-6-yl}amino)piperidinium trifluoroacetate, cis-4-( { 1 ,3-dioxo-2-[ 1 -(2-oxo-2- { [(75)- l-phenylethyl]amino} ethyl)butyl]-2,3-dihydro- IH- benzo[cfe]isoquinolin-6-yl} amino)cyclohexanecarboxylic acid, cis-4-( { 1 ,3-dioxo-2-[ 1 -(2-oxo-2- { [(75)- l-phenylethyl]amino} ethyl)butyl]-2,3-dihydro- IH- benzo[cfe]isoquinolin-6-yl} amino)cyclohexanecarboxylic acid,
2- { 1 -[(benzyloxy)methyl]butyl} -6-[(2-hydroxy ethyl) amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, trans- 1 -benzyl-4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid,
2-(3-chlorophenyl)-6- { [ 1 -(phenylacetyl)piperidin-4-yl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[cfe]isoquinolin-2(3H)-yl]benzoic acid,
1 -benzyl-4- { [2-(3-bromo-5-carboxyphenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}piperidinium trifluoroacetate,
4-[(4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}piperidinium- 1 - yl)methyl]pyridinium bis(trifluoroacetate),
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 -(3- thienylmethyl)piperidinium trifluoroacetate, c/.y-4-[(2-{3-methyl-5-[(methylamino)carbonyl]phenyl}-l,3-dioxo-2,3-dihydro-lH-benzo[fife]isoquinolin- 6-yl)amino]cyclohexanecarboxylic acid, cis- l-benzyl-4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid,
6-bromo-2-butyl- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
and their pharmaceutically acceptable salts.
For use in medicine, the salts of the compounds of formula (I) will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, fumaric acid, p-toluenesulfonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid, phosphoric acid or sulfuric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.
The salts may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed in vacuo or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.
The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible in vivo into the required compound of formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. Η. Bundgaard, Elsevier, 1985.
A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug" or "parent molecule") that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation in vivo may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulfate ester, or reduction or oxidation of a susceptible functionality.
The present invention includes within its scope solvates of the compounds of formula (I) and salts thereof, for example, hydrates. The present invention also includes within its scope any enantiomers, diastereomers, geometric isomers and tautomers of the compounds of formula (I). It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the invention.
In another aspect of the invention, there is provided a method of inhibiting hepatitis C virus polymerase and/or of treating or preventing an illness due to hepatitis C virus, the method involving administering to a human or animal (preferably mammalian) subject suffering from the condition a therapeutically or prophylactically effective amount of the pharmaceutical composition described above or of a compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof. "Effective amount" means an amount sufficient to cause a benefit to the subject or at least to cause a change in the subject's condition.
In a further embodiment of the present invention, there is provided the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, in combination with one or more other agents for the treatment of viral infections such as an antiviral agent, and/or an immunomodulatory agent such as α-, β- or γ-interferon, particularly α-interferon. Suitable antiviral agents include ribavirin and inhibitors of hepatitis C virus (HCV) polymerase, such as inhibitors of metalloprotease (NS2-3), serine protease (NS3), helicase (NS3) and RNA-dependent RNA polymerase (NS5B).
A further aspect of the invention provides a pharmaceutical composition comprising a compound of formula (Ic) or (Id) as defined above or a compound selected from Group (II) as defined above, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier. The composition may be in any suitable form, depending on the intended method of administration. It may for example be in the form of a tablet, capsule or liquid for oral administration, or of a solution or suspension for administration parenterally. The composition may be prepared by admixing at least one active ingredient, or a pharmaceutically acceptable salt thereof, with one or more pharmaceutically acceptable adjuvants, diluents or carriers and/or with one or more other therapeutically or prophylactically active agents.
A further aspect of the invention provides a compound of formula (Ic) or (Id) as defined above or a compound selected from Group (II) as defined above, or a pharmaceutically acceptable salt thereof for use in therapy.
A further aspect of the invention provides a compound of formula (Ic) or (Id) as defined above or a compound selected from Group (II) as defined above, or a pharmaceutically acceptable salt thereof.
The dosage rate at which the compound is administered will depend on a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age of the patient, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition and the host undergoing therapy. For the treatment or prevention of infection by hepatitis C virus, suitable dosage levels may be of the order of 0.02 to 5 or 10 g per day, with oral dosages two to five times higher. For instance, administration of from 10 to 50 mg of the compound per kg of body weight from one to three times per day may be in order. Appropriate values are selectable by routine testing. The compound may be administered alone or in combination with other treatments, either simultaneously or sequentially. For instance, it may be administered in combination with effective amounts of antiviral agents, immunomodulators, anti-infectives or vaccines known to those of ordinary skill in the art. It may be administered by any suitable route, including orally, intravenously, cutaneously and subcutaneously. It may be administered directly to a suitable site or in a manner in which it targets a particular site, such as a certain type of cell. Suitable targeting methods are already known.
Compounds of general formula (I) may be prepared by methods disclosed in the documents hereinbefore referred to and by methods known in the art of organic synthesis as set forth below.
According to a general process (a), compounds of formula (I) may be prepared by the reaction of a compound of formula (II) with a compound of formula (III):
Figure imgf000020_0001
(II) (III)
where R1, R2, A, B and n are as defined for formula (I). The reaction is conveniently performed in the presence of a suitable solvent, such as NMP, ethanol or DMF, at a raised temperature, such as the reflux temperature of the solvent, and optionally under microwave irradiation.
Compounds of formula (I) may also be prepared by the reaction of a compound of formula (IV) with a compound of formula (V):
Figure imgf000020_0002
(IV) (V)
where R1, R2, A and B are as defined for formula (I), and L is a suitable leaving group such as chlorine, bromine or nitro. The reaction is conveniently performed in the presence of a suitable solvent, such as NMP, at a raised temperature, optionally under microwave irradiation.
Alternatively, the compounds of formula (I) may be prepared by the reaction of the compound of formula (IV) with a compound of formula (VI): R2— B(OH)2 (VI)
where R2 is as defined for formula (I). The reaction is conveniently performed in the presence of a suitable catalyst, such as palladium triphenylphosphine, in a suitable solvent, such as a dimethyl ether/ethanol mixture, at raised temperature.
Where they are not commercially available, the starting material of formulae (II), (III), (IV) and (V) may be prepared by methods analogous to those described in the accompanying Examples, or by standard methods well known from the art.
It will be understood that any compound of formula (I) initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula (I) by techniques known from the art.
For instance, a compound of formula (I) where B is C=O may be transformed into a compound of formula (I) where B is CH2 by reduction with a suitable reducing agent, such as sodium borohydride, in a suitable solvent, such as an ethanol/water mixture.
Many of the compounds of the present invention were prepared using the general method (A):
Method A
Figure imgf000021_0001
1,8-naphthalimides were prepared by condensation reaction of naphthalic anhydrides with primary amines under microwave irradiation. The 6-amino analogues were synthesised by treatment of 6-bromo- 1,8-naphthalimides with primary or secondary amines under microwave irradiation. General method (A) is illustrated by Example 1 below.
Where a mixture of products is obtained from any of the processes described above for the preparation of compounds according to the invention, the desired product can be separated therefrom at an appropriate stage by conventional methods such as preparative HPLC; or column chromatography utilising, for example, silica and/or alumina in conjunction with an appropriate solvent system.
During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T. W. Greene & P.G.M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 3rd edition, 1999. The protecting groups may be removed at a convenient subsequent stage using methods known from the art. The following Examples are illustrative of the invention.
The compounds of the invention were tested for inhibitory activity against the HCV RNA dependent RNA polymerase (NS5B) in an enzyme inhibition assay (example i)). The compounds have IC50's below 30μM in the enzyme assay.
i) In-vitro HCV NS5B Enzyme Inhibition Assay
The HCV-BK cDNA sequence coding for the NS5B protein lacking of the 21 C-terminal residues (residues 1-570) was cloned in the pT7.7 vector downstream of the T7 promoter and in frame with the first ATG of the gene 10 protein of the T7 phage. A C-terminal HisTag was added to simplify purification procedure. Expression in E.coli BL21(DE3) was performed as described (Tomei et al., JGV (2000), 81, 759). Bacteria were grown at 37°C in standard LB medium up to an absorbance of 0.8 at 600 nm. The temperature of the culture was then lowered to 18°C and expression induced with 0.4 mM IPTG for further 23 hrs. All the subsequent purification steps were performed at 4°C. Cells were harvested, washed with PBS (20 mM Na-phosphate [pH 7.5], 150 mM NaCl), resuspendend in 100 ml of lysis buffer/liter of culture, and disrupted with a model HOS Microfluidizer. Lysis buffer contained 10 mM Tris [pH 8.0], 1 mM EDTA, 0.5 M NaCl, 50% glycerol, 10 mM β-mercaptoethanol, 0.1% n-octyl-β-D- glucopyranoside (Inalco; n-OG), Complete™ protease inhibitor cocktail (Roche). After addition of 10 mM MgCl2, the extract was incubated with 0.5 units/ml of DNaseI for 30 min. The insoluble material was pelletted by centrifugation for 60 min at 15,000 rpm in a Sorvall SS34 rotor. The clarified supernatant was incubated batchwise for 45 min with 50 ml/liter of culture of DEAE-Sepharose FF resin equilibrated in lysis buffer lacking glycerol. The flow-through from the DEAE-Sepharose was diluted to 0.3 M NaCl and loaded on a Ni-NTA Superflow column (Qiagen; 3 ml/liter of culture) equilibrated with A buffer + 10 mM Imidazole (A buffer: 10 mM Tris [pH 8.0], 20% glycerol, 0.3 M NaCl, 0.1% n-OG, 10 mM β-mercaptoethanol) and eluted with a 50 to 500 mM imidazole gradient in A buffer. Peak fraction were collected, dialysed vs D buffer (10 mM Hepes [pH 8.0], 20% glycerol, 0.2% n-OG, 1 mM EDTA, 5 mM DTT) containing 0.15 M NaCl and loaded on HiTrap Heparin column (Amersham) equilibrated with D buffer and eluted with a 0.15 to 0.8M NaCl gradient in D buffer. The protein was stored in aliquots in liquid nitrogen. The purified enzyme was shown to possess in vitro RNA polymerase activity using RNA as template according to a description in Journal of General Virology 81:759-767 (2000). The reference describes a polymerisation assay using poly(A) and oligo(U) as a template/primer. Incorporation of tritiated UTP is quantified by measuring acid-insoluble radioactivity. The present inventors have employed this assay to screen the various compounds described above as inhibitors of HCV RdRp.
Incorporation of radioactive UMP was measured as follows. The standard reaction (50 μl) was carried out in a buffer containing 20 mM Tris/HCl pH 7.5, 5 mM MgCl2, 1 mM DTT, 10 mM NaCl, 0.01% Triton X-100, 1 μCi [3H]-UTP (40 Ci/mmol, NEN), 10 μM UTP and 10 μg/ml poly(A) /Oligo(U)i2 (1 μg/ml, Genset) as a template/primer. The final NS5B ΔC21 enzyme concentration was 5 nM. The order of assembly was: 1) compound, 2) enzyme, 3) template/primer, 4) NTP. After 1 h. incubation at 22°C the reaction was stopped by adding 50 μl of 20% TCA and applying samples to DE81 filters. The filters were washed thoroughly with 5% TCA containing IM Na2HPO4ZNaH2PO4, pH 7.0, rinsed with water and then ethanol, air dried, and the filter-bound radioactivity was measured in the scintillation counter. Carrying out this reaction in the presence of various concentrations of each compound set out above allowed determination Of IC50 values by utilising the formula:
% Residual activity = 100/(l+[I]/IC50)s
where [I] is the inhibitor concentration and "s" is the slope of the inhibition curve.
ii) General Procedures
AU solvents were obtained from commercial sources (Fluka, puriss.) and were used without further purification. With the exception of routine deprotection and coupling steps, reactions were carried out under an atmosphere of nitrogen in oven dried (110 °C) glassware. Organic extracts were dried over sodium sulfate, and were concentrated (after filtration of the drying agent) on rotary evaporators operating under reduced pressure. Flash chromatography was carried out on silica gel following published procedure (W.C. Still et al., J. Org. Chem. 1978, 43, 2923) or on semi-automated flash chromatography systems utilising pre-packed columns.
Reagents were usually obtained directly from commercial suppliers (and used as supplied) but a limited number of compounds from in-house corporate collections were utilised. In the latter case the reagents are readily accessible using routine synthetic steps that are either reported in the scientific literature or are known to those skilled in the art.
1H nmr spectra were recorded on Bruker AM series spectrometers operating at (reported) frequencies between 300 and 600 MHz. Chemical shifts (δ) for signals corresponding to non- exchangeable protons (and exchangeable protons where visible) are recorded in parts per million (ppm) relative to tetramethylsilane and are measured using the residual solvent peak as reference. Signals are tabulated in the order: multiplicity (s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad, and combinations thereof); coupling constant(s) in hertz; number of protons. Mass spectral (MS) data were obtained on a Perkin Elmer API 100 operating in negative (ES") or positive (ES+) ionization mode and results are reported as the ratio of mass over charge (m/z) for the parent ion only. Preparative scale HPLC separations were carried out on a Waters Delta Prep 4000 separation module, equipped with a Waters 486 absorption detector or on a Gilson preparative system. In all cases compounds were eluted with linear gradients of water and acetonitrile both containing 0.1% TFA using flow rates between 15 and 25 mL/min.
The following abbreviations are used in the examples: AcOH: acetic acid; BINAP: 2,2'-bis(diphenylphosphino)-l,r-binaphthyl; BoC2O: di-tert-butyl dicarbonate; DIPEA: NN-diisopropylethylamine; DMAP: 4-(dimethylamino)pyridine; DME: 1,2- dimethoxyethane; DMF: dimethylformamide; DMSO: dimethylsulfoxide; eq.: equivalents); EtOH: ethanol; H2O: water; Et2O: ethyl ether; EtOAc: ethyl acetate; h: hour(s); HCl: hydrogen chloride; M: molar; MeCN: acetonitrile; MeOH: methanol; min: minutes; ΝMP: l-methyl-2-pyrrolidinone; RP-HPLC: reversed phase high-pressure liquid chromatography; RT: room temperature; TFA: trifluoroacetic acid.
Example 1: lH-benz[cfe]isoquinoline-l,3(2H)-dione, 2-(3-bromophenyl)-6-[(2-hydroxyethyl)amino]
Step 1 : 6-bromo-2-(3-bromophenyiy lH-benzo[<fe]isoquinoline- 1 ,3(2H)-dione
3-bromoaniline (1.3 eq.) was added to a solution (0.3 M) of 4-bromo-l,8-naphthalic anhydride in ΝMP. The reaction mixture was heated at 145°C for 24 h and then cooled at RT. The resulting precipitate was filtered, washed subsequently with EtOH and Et2O and dried to afford the title compound (42%) as a pale brown solid; MS (ES+) m/z 430, 432 (M+Η)+.
Step 2: 2-(3-bromophenyl)-6-[(2-hvdroxyethyl)aminol- lH-benz[<felisoquinoline-1.3(2H)-dione
A solution (0.2 M) of 6-bromo-2-(3-bromophenyl)-lH-benzo[cfe]isoquinoline-l,3(2H)-dione (from Step
1) and ethanolamine (10 eq.) in ΝMP was heated at 200°C under microwave irradiation for 30 min. After addition of water the resulting precipitate was filtered and washed subsequently with EtOH and Et2O.
Crystallization from acetone afforded the title compound (27%) as a yellow solid.
1H ΝMR (400 MHz, DMSO-d6, 400 K) δ 3.51 (m, 2H), 3.73 (m, 2H), 4.91 (t, / 5.19, IH), 6.87 (d, / 8.57,
IH), 7.38 (d, / 7.67, IH), 7.48 (t, / 7.75, IH), 7.65 (m, 2H), 7.73 (t, / 7.76, IH), 8.27 (d, / 8.48, IH), 8.45
(d, /7.13, IH), 8.77 (d, / 8.30, IH); MS (ES+) m/z 411, 413 (M+H)+ .
Example 2: 2-(3-chlorophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione A solution (0.09 M) of 4-bromo-l,8-naphthalic anhydride in EtOH was treated with 3-chloroaniline (1.5 eq.). The reaction mixture was heated to reflux for 15 h. After cooling down, filtration and washing with EtOH afforded a solid that was a mixture (1.2:1) of starting material and 6-bromo-2-(3-chlorophenyl)-lH- benzo[fife]isoquinoline-l,3(2H)-dione (MS (ES+) m/z 386, 388, 390 (M+Η)+). This crude was dissolved in ΝMP. The resulting solution (0.15 M) was treated with 2-aminoethanol (2.0 eq.). The reaction mixture was heated at 200°C under microwave irradiation for 30 min. After cooling down, the reaction mixture was diluted with MeCΝ/DMSO (3:1) and it was purified by RP-HPLC (Conditions: Waters X-TERRA MS C18, 5 micron, 19 x 150 mm; flow: 20 mL/min; Gradient: A: H2O + 0.1% TFA; B: MeCN + 0.1% TFA; 99% A isocratic for 2 min, linear to 1% A in 10 min, 1% A isocratic for 5 min) to afford the title compound (20%) as a solid. 1H NMR (400 MHz, DMSO-d6, 300 K) δ 3.50 (m, 2H), 3.72 (t, 2H, / 6.2), 6.86 (d, IH, / 8.6), 7.33 (m, IH), 7.52 (m, 3H), 7.72 (dd, IH, / 7.2, 8.3), 7.80 (m, IH), 8.26 (d, IH, / 8.6), 8.44 (d, IH, / 7.2), 8.75 (d, IH, / 7.9); MS (ES+) m/z 367, 369 (M+H)+.
Example 3: 2-butyl-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione
Step 1: 6-bromo-2-butyl-lH-benzo[(Je1isoquinoline-1.3(2H)-dione
A solution (0.32 M) of 4-bromo-l,8-naphthalic anhydride in EtOH was treated with w-butylamine (1.1 eq.). The reaction mixture was heated at 150°C under microwave irradiation for 1 h. After addition of MeOH the resulting precipitate was filtered and dried to afford a first crop of the title compound (62%) as a solid. The filtrate was concentrated, and the residue was treated with EtOHZH2O (1:4) to afford a second crop of the title compound (35%). This compound was used as such in the next step; MS (ES+) m/z 332, 334 (M+H)+.
Step 2: 2-butyl-6-[(2-hvdroxyethyl)aminol-lH-benzo[(Je1isoquinoline-l,3(2H)-dione A solution (0.15 M) of 6-bromo-2-butyl-lH-benzo[cfe]isoquinoline-l,3(2H)-dione (from Step 1) in NMP was treated with 2-aminoethanol (1.2 eq.). The reaction mixture was heated at 200°C under microwave irradiation for 30 min. After cooling down, the reaction mixture was diluted with EtOAc and water was added. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried and evaporated to give a residue that was purified by RP-ΗPLC (Conditions: Waters X-TERRA MS C 18, 5 micron, 19 x 150 mm; flow: 20 mL/min; Gradient: A: H2O + 0.1% TFA; B: MeCN + 0.1% TFA; 99% A isocratic for 2 min, linear to 1% A in 10 min, 1% A isocratic for 5 min) to afford the title compound (53%) as a solid.
1H NMR (400 MHz, DMSO-d6, 300 K) δ 0.91 (t, 3H, /7.2), 1.33 (m, 2H), 1.58 (m, 2H), 3.46 (m, 2H), 3.70 (t, 2H, / 6.1), 4.04 (t, 2H, / 7.4), 6.81 (d, IH, / 8.8), 7.67 (dd, IH, / 7.4, 8.3), 7.70 (bs, IH), 8.25 (d, IH, / 8.6), 8.42 (d, IH, /6.8), 8.68 (d, IH, / 7.6); MS (ES+) m/z 313 (M+H)+.
Example 4: 2-(3-bromophenyl)-6-[(2-hydroxyethyl)thio]-lH-benzo[cfe]isoquinoline-l,3(2H)-dione A solution (1.0 M) of 6-[(2-hydroxyethyl)thio]-lH, 3H-benzo[cfe]isochromene-l,3-dione in NMP was treated with 3-bromoaniline (1.5 eq.). The reaction mixture was heated at 200°C under microwave irradiation for 30 min. Then more 3-bromoaniline (0.75 eq) was added, and the reaction was heated under microwave irradiation for another 15 min. After cooling down, water and EtOAc were added. The layers were separated, and the aqueous layer was extracted with EtOAc. The gummy residue that remained on the reaction vessel gave a solid after addition of EtOH. This solid was filtered off and washed with EtOH to afford 39% of recovered starting material. After drying, combined EtOAc layers were joint with the EtOH filtrate and evaporated. The residue was purified by RP-ΗPLC (Conditions: Waters X-TERRA MS C 18, 5 micron, 19 x 150 mm; flow: 20 mL/min; Gradient: A: H2O + 0.1% TFA; B: MeCN + 0.1% TFA; 99% A isocratic for 2 min, linear to 1% A in 10 min, 1% A isocratic for 5 min) to afford the title compound (11%) as a solid.
1H NMR (400 MHz, DMSO-d6, 300 K) δ 3.39 (t, 2H, /6.4), 3.77 (t, 2H, /6.4), 5.14 (bs, IH), 7.43 (d, IH, /7.9), 7.50 (t, IH, / 7.9), 7.68 (d, IH, / 7.9), 7.70 (d, IH, / 1.5), 7.85 (d, IH, / 8.1), 7.93 (dd, IH, / 7.4, 8.3), 8.38 (d, IH, / 7.9), 8.55 (d, IH, /7.2), 8.65 (d, IH, / 8.5); MS (ES+) m/z 428, 430 (M+H)+.
Example 5: 2-(3-bromophenyl)-7-[(2-hydroxyethyl)amino]-2,3-dihydro-lH-benzo[fife]isoquinolin-l- one
A solution (0.02 M) of 2-(3-bromophenyl)-6-[(2-hydroxyethyl)amino]-lH-benz[cfe]isoquinoline-l,3(2H)- dione (from Example 1) in EtOΗ/water (10: 1) was treated with sodium borohydride (5 eq.). The reaction was stirred overnight at RT. After quenching with aqueous HCl (1 N), the reaction mixture was extracted with EtOAc and the combined organic layers were dried and concentrated. The residue was purified by RP-ΗPLC (Conditions: Waters X-TERRA MS C 18, 5 micron, 19 x 150 mm; flow: 20 mL/min; Gradient: A: H2O + 0.1% TFA; B: MeCN + 0.1% TFA; 90% A isocratic for 2 min, linear to 30% A in 10 min, then linear to 0% A in 2 min) to afford the title compound (26%) as a solid.
1H NMR (300 MHz, DMSO-d6, 300 K) δ 3.41 (m, 2H), 3.70 (m, 2H), 4.83 (t, / 5.53, IH), 5.29 (s, 2H), 6.68 (d, / 8.40, IH), 6.91 (m, IH), 7.35-7.55 (m, 5H), 7.74 (s, IH), 8.06 (d, / 8.41, IH), 8.15 (m, IH); MS (ES+) m/z 397, 399 (M+H)+.
Example 6: 2-(3-chlorophenyl)-6-(3-hydroxypropyl)-lH-benzo[cfe]isoquinoline-l,3(2H)-dione
Step 1: 2-(3-chlorophenyl)-6-[(lJD-3-hvdroxyprop-l-en-l-yl1-lH-benzo[(Je1isoquinoline-1.3(2H)-dione A solution (0.1 M) of 6-bromo-2-(3-chlorophenyl)-lH-benzo[cfe]isoquinoline-l,3(2H)-dione (prepared as in Example 2) in DMF was treated with prop-2-en-l-ol (10 eq.), palladium acetate (0.05 eq.), triphenylphosphine (0.1 eq.) and silver acetate (1.0 eq.). The reaction mixture was heated at 80°C for 12 h. After cooling down, the reaction mixture was diluted with EtOAc and aqueous HCl (IN) was added. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried and evaporated to give a yellow solid as residue that was used as such in the next step; MS (ES+) m/z 364, 366 (M+Η)+.
Step 2: 2-(3-chlorophenyl)-6-(3-hvdroxypropyl)- lH-benzo[<fe1isoquinoline- 1 ,3(2H)-dione A solution (0.1 M) of 2-(3-chlorophenyl)-6-[(l£)-3-hydroxyprop-l-en-l-yl]-lH-benzo[cfe]isoquinoline- l,3(2H)-dione (from step 1) in MeOΗ/EtOAc (1:1) was treated with ZnBr2 (0.2 eq.), 10% Pd on carbon (50% w/w) and stirred under H2 (g) for 12 h. The catalyst was then deactivate by bubbling N2 for 10 min, filtered off and washed with hot MeOH and EtOAc. The solution was evaporated to give a residue that was purified by RP-HPLC (Conditions: Waters Symmetry C 18, 5 micron, 19x300 mm; flow: 20 mL/min; Gradient: A: H2O + 0.1 %TFA; B: MeCN + 0.1% TFA; 60 % A isocratic for 3 min, linear to 10 % A in 23 min, 10 % A isocratic for 2 min) to afford the title compound (6% over two steps) as a solid. 1H NMR (400 MHz, DMSO-d6, 300 K) δ 1.81-1.92 (m, 2H), 3.20-3.35 (m, 2H), 3.49-3.58 (m, 2H), 4.60- 4.70 (m, IH), 7.38-7.44 (m, IH), 7.52-7.62 (m, 3H), 7.77 (d, / 7.5, IH), 7.93 (t, / 7.9, IH), 8.44 (d, / 7.5, IH), 8.52 (d, / 7.2, IH), 8.67 (d, / 8.40, IH); MS (ES+) m/z 366, 368 (M+H)+.
Example 7: 2-(3-chlorophenyl)-6-(lH-pyrazol-3-yl)-lH-benzo[cfe]isoquinoline-l,3(2H)-dione A solution (0.1 M) of 6-bromo-2-(3-chlorophenyl)-lH-benzo[cfe]isoquinoline-l,3(2H)-dione (prepared as in Example 2) in DME/EtOΗ (2.6/1) was treated with lH-pyrazol-3-yl boronic acid (1.2 eq.), aqueous Na2CO3 (2M solution) and Pd(PPh3)4 (0.1 eq.). The reaction mixture was heated at 80°C for 2 h. After cooling down, the reaction mixture was acidified with aqueous HCl (IN) and filtered. The precipitate was washed sequentially with water, a small portion Of Et2O and dried to give a residue that was purified by RP-ΗPLC (Conditions: Waters X-TERRA C18, 5 micron, 19x100 mm; flow: 20 mL/min; Gradient: A: H2O + 0.1 %TFA; B: MeCN + 0.1% TFA; 50 % A isocratic for 1 min, linear to 0 % A in 9 min, 0 % A isocratic for 2 min) to afford the title compound (25%) as a solid.
1H NMR (400 MHz, DMSO-d6, 300 K) δ 6.96 (d, /2.2, IH), 7.41-7.50 (m, IH), 7.55-7.65 (m, 3H), 7.97 (dd, /7.5, 8.56, IH), 8.02 (d, /2.2, IH), 8.16 (d, /7.7, IH), 8.54-8.60 (m, 2H), 9.30-9.45 (bs, IH); MS (ES+) m/z 374, 376 (M+H)+.
Example 8: 3-[6-[(benzylamino)carbonyl]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]hexanoic acid
Step 1: l,3-dioxo-lH,3H-benzo[(Je1isochromene-6-carboxylic acid
A solution (0.4 M) of l^-dihydroacenaphthylene-S-carboxylic acid in glacial AcOH was treated with Na2Cr2O7 (4.0 eq.). After the spontaneous exothermic reaction was finished the reaction mixture was heated at reflux for 10 min. The reaction mixture was then cooled down, acidified with aqueous HCl (IN) and the precipitate formed was filtered, washed with water and dried to give the title compound (50%) as a solid; MS (ES+) m/z 243 (M+Η)+.
Step 2: 3-[6-[(benzylamino)carbonyl1-l,3-dioxo-lH-benzo[de1isoquinolin-2(3H)-yllhexanoic acid A solution (0.4 M) of l,3-dioxo-lH,3H-benzo[cfe]isochromene-6-carboxylic acid (from step 1) in CH2Cl2 was treated with DMF (0.05 eq.) and cooled to 00C. Oxalyl chloride (2M solution in CH2Cl2, 2.0 eq.) was added and the reaction mixture was stirred at 0°C for 1 h., then at 25°C for 1 h. The solvent was removed in vacuo and the residue was dissolved in toluene/DMF (1/1). The resulting solution (0.1 M) was treated with benzylamine (0.98 eq.) and a catalytic amount of DMAP. The reaction mixture was stirred at 25°C for 1 h., then at 60°C for 6 h. After cooling down, the reaction mixture was diluted with EtOAc and aqueous HCl (IN) was added. The organic layer was separated and the aqueous layer was extracted with EtOAc. The combined organic layers were washed with brine, dried and evaporated to give a brown solid as residue that was used as such after dilution in EtOH. The resulting solution (0.14 M) was treated with β-norvaline (3.0 eq.). The reaction mixture was heated at 150°C under microwave irradiation for 30 min. After cooling down, the solvent was evaporated and the residue was purified by RP-HPLC (Conditions: Waters X-TERRA C 18, 5 micron, 19x100 mm; flow: 20 mL/min; Gradient: A: H2O + 0.1 %TFA; B: MeCN + 0.1% TFA; 50 % A isocratic for 1 min, linear to 0 % A in 9 min, 0 % A isocratic for 2 min) to afford the title compound (22%) as a solid.
1H NMR (400 MHz, DMSO-d6, 300 K) δ 0.86 (t, / 7.32, 3H), 1.19-1.31 (m, 2H), 1.69-1.81 (m, IH), 2.10- 2.22 (m, IH), 2.90 (dd, / 6.9, 16.0, IH), 3.08 (dd, / 7.7, 16.0, IH), 4.59 (d, / 5.9, 2H), 5.42-5.53 (m, IH), 7.27-7.33 (m, IH), 7.36-7.46 (m, 4H), 7.92 (t, /7.9, IH), 7.97 (d, / 7.5, IH), 8.49-8.57 (m, 2H), 8.59 (d, / 8.4, IH), 9.37 (bt, / 5.94, IH), 12.0-12.4 (bs, IH); MS (ES+) m/z 445 (M+H)+.
Example 9: 6-[(2-hydroxyethyl)amino]-2-[(5-methylisoxazol-3-yl)methyl]-lH- benzo[fife]isoquinoline-l,3(2H)-dione
Step 1: feft-butyl 6-bromo-1.3-dioxo-lH-berizo[<fe]isoquinoline-2(3H)-carboxylate A solution (0.9 M) of 6-bromo-lH,3H-benzo[cfe]isochromene-l,3-dione in EtOH and ammonia (32% aqueous solution, 1 eq.) were mixed in an Ace tube. The tube was well closed and heated at 80°C for 3 h. After cooling down, a precipitate was formed. The precipitate was isolated by filtration and washed with small portions of EtOH. The resulting solid was dissolved in dioxane. The resulting solution (0.2 M) was treated with BoC2O (1.2 eq.) and catalytic amount of DMAP. The reaction mixture was stirred at RT for Ih. Then, the solvent was evaporated and the residue was diluted with EtOAc and washed with aqueous HCl (IN), NaHCO3 (saturated solution), brine and dried. Evaporation of the solvent afforded the title compound (85%) as pale yellow powder; m/z 276,278 (M+H)+.
Step 2: 6- { [2-(benzyloxy)ethyl]amino| - lH-benzo[<fe1isoquinoline- 1 ,3(2H)-dione A solution (0.5 M) of tert-butyl 6-bromo-l,3-dioxo-lH-benzo[cfe]isoquinoline-2(3H)-carboxylate (from step 1) and 2-(benzyloxy)ethanamine (3 eq.) in NMP (0.5 M) was heated at 180°C under microwave irradiation for 30 min. Then, the reaction was treated with water and kept at 4°C overnight. The resulting precipitate was isolated by filtration giving the title compound (70%) as a solid; m/z 347 (M+Η)+.
Step 3: 6-[(2-hydroxyethyl)amino]-2-[(5-methylisoxazol-3-yl)methyl]- lH-benzo[<fe]isoquinoline-
1.3f2H)-dione
A solution (0.4 M) of 6-{[2-(benzyloxy)ethyl]amino}-lH-benzo[cfe]isoquinoline-l,3(2H)-dione in DMF was treated with KOΗ (1.1 eq.) and stirred for 30 min at 0°C. Then, 3-(chloromethyl)-5-methylisoxazole
(1.2 eq.) was added and the reaction was stirred overnight. The reaction was treated with NH4Cl
(saturated solution) and extracted with EtOAc. The recombined organic layers were washed with NH4Cl (saturated solution), water, brine and dried. Evaporation of the solvent afforded a crude that was dissolved in MeOH. 10% Pd on carbon (50% w/w) was added to the resulting solution (0.1 M). The reaction was stirred under H2 for 2 h. at RT. Then, the catalyst was filtered off and washed with EtOAc. After evaporation of the solvent the resulting residue was diluted with MeCN/DMSO (3:1) and purified by RP-HPLC (Conditions: Waters X-TERRA MS C 18, 5 micron, 19 x 100 mm; flow: 20 mL/min; Gradient: A: H2O + 0.1% TFA; B: MeCN + 0.1% TFA; 80% A isocratic for 1 min, linear to 20% A in 9 min, 20% A isocratic for 2 min) affording the title compound (37%) as a solid. 1H NMR (300 MHz, DMSO-d6, 300 K) δ 2.32 (s, 3H), 3.50 (m, 2H), 3.70 (m, 2H), 4.88 (t, / 5.5, IH), 5.21 (s, 2H), 6.85 (d, / 8.6, IH), 7.70 (t, / 8.0, 1 H), 7.80 (m, IH), 7.99 (m, IH), 8.29 (d, / 8.6, IH), 8.46 (d, /7.1, IH), 8.74 (d, / 8.2 ,1H); m/z 353 (M+H)+.
Example 10: d.y^-IP-CS-chloropheny^-l^-dioxo^^-dihydro-lH-benzotfifelisoquinolin-ό- yl]amino}cyclohexanecarboxylic acid
Step 1: methyl cis-4-{[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[(Je1isoquinolin-6- yl]amino| cyclohexanecarboxylate
A solution (0.1 M) of 6-bromo-2-(3-chlorophenyl)-lH-benzo[cfe]isoquinoline-l,3(2H)-dione (prepared as in Example 2), methyl cώ-4-aminocyclohexanecarboxylate hydrochloride (1.2 eq.) and DIPEA (1.5 eq.) in dry and degassed toluene was treated sequentially with BINAP (0.03 eq.), Pd(OAc)2 (0.02 eq.), and NaOf-Bu (1.4 eq.). The reaction was stirred at 80°C for 2 h., then additional amounts of reagents: BINAP (0.06 eq.), Pd(OAc)2 (0.08 eq.), and NaOf-Bu (1.4 eq.) were added. The reaction was stirred for another 3 h. and then diluted with EtOAc and water. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried and concentrated to give a residue that was purified by chromatography on silica gel (petroleum ether/EtOAc (7:3) to EtOAc) to afford the title compound (43%) as a solid; MS (ES+) m/z 463, 465 (M+Η)+.
Step 2: cis-4- { [2-(3-chlorophenvD- 1 ,3-dioxo-2,3-dihydro- lH-benzo[<fe1isoquinolin-6- yl]amino| cyclohexanecarboxylic acid
A solution (0.075 M) of methyl ri.y-4-{[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH- beiizo[de]isoquinolin-6-yl]amino} cyclohexanecarboxylate in MeOH was treated with NaOH (2M aqueous solution, 2 eq.). The reaction mixture was heated at 60°C for 8 h. Then the solvent was evaporated under reduced pressure and the residue was taken up with EtOAc and aqueous HCl (IN) was added. The layers were separated and the aqueous layer was extracted with EtOAc. The combined organic layers were dried and concentrated. The residue was purified by RP-ΗPLC (Conditions: Waters Symmetry Prep C18, 7 micron, 19 x 300 mm; flow: 15 mL/min; Gradient: A: H2O + 0.1% TFA; B: MeCN + 0.1% TFA; 90% A to 0% A linear in 15 min) to afford the title compound (47%) as a solid. 1H NMR (400 MHz, DMSO-d6, 300 K) δ 1.69 (m, 4H), 1.87 (m, 2H), 2.10 (m, 2H), 2.59 (m, IH), 3.75 (m, IH), 6.89 (d, / 8.8, IH), 7.32 (m, IH), 7.40 (d, / 6.6, IH), 7.51 (m, 3H), 7.68 (t, /7.8, IH), 8.24 (d, / 8.5, IH), 8.42 (dd, /7.2, IH), 8.85 (d, / 8.5, IH); MS (ES+) m/z 449, 451 (M+H)+.
The following table shows additional examples which were prepared using procedures analogous to the general methods or specific examples described above, or which are commercially available, as indicated in the final column.
Table 1
Figure imgf000030_0001
Figure imgf000031_0001
Table 2
Figure imgf000031_0002
Figure imgf000032_0001
Figure imgf000033_0001
Figure imgf000034_0001
Figure imgf000035_0001
Figure imgf000036_0001
Figure imgf000037_0001
Figure imgf000038_0001
Sources of commercially available compounds: comm1: Asinex (Russia); comm2: Interchim Intermediates (France); comm3: Maybridge (UK); comm4:
Labotest (Germany) ; comm5 : Chembridge (San Diego, USA).

Claims

Claims
1. Use of a compound of formula (I):
Figure imgf000040_0001
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein
A and B are each independently CH2, C=O or C=S, with the proviso that A and B are not both CH2;
R1 is Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, (CH2)0-3C3-7cycloalkyl, (CH2)0-3Het, (CH2)0-3aryl or (CH2)0-3heteroaryl, optionally substituted by halogen, hydroxy, Ci-6alkyl, Ci-6alkoxy, C2-6alkenyl, CN, (CH2)0-3θ(CH2)o-3aryl, S(Ci-6alkyl), S(O)(Ci-6alkyl), S(O)2(Ci-6alkyl), S-heteroaryl, S(O)heteroaryl, S(O)2heteroaryl, S-aryl, S(O)aryl, S(O)2aryl, SO2NR4R5, CO2R4, CONR4R5, NR4COR5, NR4SO2R5 or NR4CONR5 where said Ci-6alkyl, (CH2)0-3Het, (CH2)0-3aryl and (CH2)0-3heteroaryl groups, either by themselves or as part of other substituents, may optionally be substituted by 1 to 8 halogen atoms, and where said (CH2)0-3Het, (CH2)0-3aryl and (CH2)0-3heteroaryl groups may optionally be further substituted with one or two groups selected from hydroxy, Ci-6alkoxy, Ci-6alkyl, (CH2)0-3CO2H, (CH2)0-3CO2Ci.6alkyl and C(O)NR24R25, and where said (CH2)0-3aryl group may be fused to C3-7cycloalkyl;
R4, R5 and R21 are each independently selected from hydrogen, Ci-6alkyl, (CH2)0-3Het, (CH2)o-3aryl, (CH2)0-3heteroaryl and SO2(Ci-6alkyl), optionally substituted by 1 to 5 halogen atoms and/or 1 or 2 groups selected from hydroxy, Ci-6alkyl, NH2 and Ci-6alkoxy;
R2 is halogen, hydroxy, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, Ci-6alkoxy, (CH2)0-3C3-8cycloalkyl, (CH2)o-3aryl, CN, NO2, NR6R7, OR8, C(O)C i-6alkyl, CO2H, CO2R8, CONR8R20, NR21COR8, NR21SO2R8, NR8CONR20, SR8, SOR8, SO2R8 or SO2NR8R20, where said Ci-6alkyl, C2-6alkenyl, Ci-6alkoxy and aryl groups are optionally substituted by 1 or 2 groups selected from halogen, hydroxy, Ci-6alkyl, Ci-6alkoxy, NH2, SO2NR6R7, CO2R6 and CONR6R7;
R6 and R7 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, (CH2)o-3C3-7cycloalkyl, (CH2)0-3Het, (CH2)0-3aryl, (CH2)0-3heteroaryl, (CH2)0-3OR9, (CH2)0-3SR9, (CH2)Q-3NR10R11, -C(CH2OH)3, COR22, C(O)C(O)OCi-6alkyl, CO2R22, CONR22R23, SO2R22 and SO2NR22R23, where said Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, cycloalkyl, Het, aryl and heteroaryl groups are optionally substituted by 1 or 2 groups selected from halogen, hydroxy, Ci-6alkyl, CF3, NH2, N(C1-6alkyl)2, SO2aryl, SO2NR18R19, (CH2)0-3aryl, (CH2)0-3heteroaryl, C(O)C 1-6alkyl, C(O)(CH2)0-3aryl, (CH2)O-3CO2R18, (CH=CH)CO2R18, CONR18R19 and O(CH2)0-3aryl, which optional aryl substituents are further optionally substituted by CO2H or Het;
R18 and R19 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, (CH2)o-3C3-7cycloalkyl, (CH2)0-3Het, (CH2)0-3aryl, (CH2)0-3heteroaryl, (CH2)0-3OR9, (CH2)0-3SR9, (CH2)O-3NR10R11, -C(CH2OH)3, where said Ci-6alkyl, C2-6alkenyl and Ci-6alkoxy groups are optionally substituted by halogen or hydroxy;
R9, R10 and R11 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, C(O)Ci-6alkyl and aryl; or R6, R7 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, which ring optionally contains 1, 2 or 3 additional heteroatoms selected from O and S or a group S(O), S(O)2 or NR12, where R12 is hydrogen, Ci-6alkyl, C2-6alkenyl or aryl, and which ring is optionally substituted by halogen, hydroxy, Ci-6alkyl, C2-6alkenyl, Ci-6alkoxy, oxo, SO2NR18R19, COR18, CO2R18 or CONR18R19 , and which ring is optionally bridged by -CH2- or -CH2CH2-;
R8, R20, R22 and R23 are each independently selected from hydrogen, Ci-6alkyl, (CH2)i-3OR13, (CH2)1-3NR14R15, (CH2)o-3aryl and (CH2)0-3heteroaryl;
R13, R14 and R15 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, aryl, C(O)R16 and C(O)OR17 ;
R16, R17 and R24 are independently selected from hydrogen, Ci-6alkyl and aryl;
R25 is hydrogen, Ci-6alkyl, (CH2)i-3CO2H, (CH2)0-3C3-8cycloalkyl, (CH2)0-3phenyl or SO2(Ci-6alkyl), where C3-8cycloalkyl and phenyl are optionally substituted by 1 to 3 groups selected from halogen, hydroxy or CO2H; n is O or 1 or 2, and when n is 2, the R2 groups may be the same or different;
Ra is hydrogen, or R2 and Ra are joined to form a 5- to 8-membered carbocyclic ring.
2. Use as claimed in Claim 1 of a compound of formula (Ii):
Figure imgf000041_0001
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein
A and B are each independently CH2, C=O or C=S, with the proviso that A and B are not both CH2; R1 is Ci-6alkyl, C2-6alkenyl, C2-6alkynyl, (CH2)o-3C3-7cycloalkyl, (CH2)0-3Het, (CH2)0-3aryl or (CH2)0-3heteroaryl, optionally substituted by halogen, hydroxy, Ci-6alkyl, Ci-6alkoxy, C2-6alkenyl, CN, S(Ci-6alkyl), S(O)(Ci-6alkyl), S(O)2(Ci-6alkyl), S-heteroaryl, S(O)heteroaryl, S(O)2heteroaryl, S-aryl, S(O)aryl, S(O)2aryl, SO2NR4R5, CO2R4, CONR4R5, NR4COR5, NR4SO2R5 or NR4CONR5 where said Ci-6alkyl and (CH2)0-3aryl groups, either by themselves or as part of other substituents, may optionally be substituted by 1 to 8 halogen atoms;
R4, R5 and R21 are each independently selected from hydrogen, Ci-6alkyl, (CH2)0-3Het, (CH2)0-3aryl and (CH2)0-3heteroaryl;
R2 is halogen, hydroxy, Ci-6alkyl, C2-6alkenyl, Ci-6alkoxy, CN, NO2, NR6R7, OR8, CO2H, CO2R8, CONR8R20, NR21COR8, NR21SO2R8, NR8CONR20, SR8, SOR8, SO2R8 or SO2NR8R20, where said Ci-6alkyl, C2-6alkenyl and Ci-6alkoxy groups are optionally substituted by halogen, hydroxyl, SO2NR6R7, CO2R6 or CONR6R7;
R6 and R7 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, (CH2)O-3C3-7CyClOaIlCyI, (CH2)0-3Het, (CH2)0-3aryl, (CH2)0-3heteroaryl, (CH2)0-3OR9, (CH2)0-3SR9, (CH2)Q-3NR10R11, -C(CH2OH)3, COR22, CO2R22, CONR22R23, SO2R22 and SO2NR22R23, where said Ci-6alkyl, C2-6alkenyl, cycloalkyl, Het, aryl and heteroaryl groups are optionally substituted by halogen, hydroxy, SO2NR18R19, CO2R18 or CONR18R19;
R18 and R19 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, (CH2)o-3C3-7cycloalkyl, (CH2)0-3Het, (CH2)0-3aryl, (CH2)0-3heteroaryl, (CH2)0-3OR9, (CH2)0-3SR9, (CH2)O-3NR10R11, -C(CH2OH)3, where said Ci-6alkyl, C2-6alkenyl and Ci-6alkoxy groups are optionally substituted by halogen or hydroxy;
R9, R10 and R11 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, C(O)Ci-6alkyl and aryl; or R6, R7 and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms, which ring optionally contains 1, 2 or 3 additional heteroatoms selected from O and S or a group S(O), S(O)2 or NR12, where R12 is hydrogen, Ci-6alkyl, C2-6alkenyl or aryl, and which ring is optionally substituted by halogen, hydroxy, Ci-6alkyl, C2-6alkenyl or Ci-6alkoxy, carboxyl, SO2NR18R19, COR18, CO2R18 or CONR18R19;
R8, R20, R22 and R23 are each independently selected from Ci-6alkyl, (CH2)i-3OR13, (CH2)1-3NR14R15, (CH2)o-3aryl and (CH2)0-3heteroaryl;
R13, R14 and R15 are each independently selected from hydrogen, Ci-6alkyl, C2-6alkenyl, aryl, C(O)R16 and C(O)OR17 ;
R16 and R17 are independently selected from hydrogen, Ci-6alkyl and aryl; n is O or 1.
3. Use as claimed in Claim 1 or Claim 2 wherein one of A or B is C=O and the other is CH2 or C=O.
4. Use as claimed in Claim 3 wherein A is C=O and B is CH2 or C=O.
5. Use as claimed in Claim 4 wherein A and B are C=O.
6. Use as claimed in any one of Claims 1 to 5 wherein R1 is (CH2)o-3aryl, optionally substituted by halogen, hydroxy, Ci-6alkyl, Ci-6alkoxy, C2-6alkenyl, CN, S(CX-6 alkyl), S(O)(Ci-6alkyl), S(O)2(Ci-6alkyl), SO2NR4R5 where R4 and R5 are as defined in Claim 1.
7. Use as claimed in any one of Claims 1 to 6 wherein R2 is NR6R7 where R6 and R7 are as defined in Claim 1.
8. Use as claimed in Claim 7 wherein R6 and R7 are independently selected from hydrogen, Ci-6alkyl, (CH2)0-3C3-7cycloalkyl, (CH2)0-3OR9 where R9 is as defined in Claim 1.
9. Use as claimed in Claim 1 of a compound of formula (Ia):
Figure imgf000043_0001
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein R1 and R2 are as defined in Claim 1.
10. Use as claimed in Claim 9 wherein R1 is (CH2)0-3aryl, optionally substituted by halogen, hydroxy, Ci-6alkyl, Ci-6alkoxy, C2-6alkenyl, CN, S(Ci-6alkyl), S(O)(Ci-6alkyl), S(O)2(Ci-6alkyl), SO2NR4R5 where R4 and R5 are as defined in Claim 1.
11. Use as claimed in Claim 9 or Claim 10 wherein R2 is NR6R7 where R6 and R7 are as defined in Claim 1.
12. Use as claimed in Claim 11 wherein one of R6 and R7 is hydrogen and the other is selected from Ci-6alkyl, (CH2)0-3C3.7cycloalkyl or (CH2)0-3θR9, where R9 is as defined in Claim 1.
13. Use as claimed in Claim 1 of a compound of formula (Ib):
Figure imgf000044_0001
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein
R2 is as defined in Claim 1 , and
R1 is phenyl substituted by bromine and/or CO2H, optionally further substituted by halogen, hydroxy, C2-6alkyl, Ci-6alkoxy or CH2CO2H.
14. Use as claimed in Claim 1 of a compound of formula (Ic):
Figure imgf000044_0002
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein R1 is as defined in Claim 1, and R2 is C3-8cycloalkyl, (CH2)1-6OH, C2-8alkoxy, phenyl,
NH(CH2)0-3Het substituted by C(O)(CH2)0-3aryl, C(O)(Ci-6alkyl), C(O)C3-8cycloalkyl, SO2aryl, (CH2)i-3aryl (optionally substituted by CO2Ci-6alkyl or (CH2)0-3CO2H), (CH2)i-3heteroaryl or (CH2)i-3C(O)OCi-6alkyl, NH(CH2)0-3C3.8cycloalkyl substituted by CO2H or CO2(Ci-6alkyl), NHC(O)Ci-6alkyl, NHC(0)(CH2)o-3aryl, NH(CH2)2O(CH2)1-3aryl, 3-oxo-2-azabicyclo[2.2.2]oct-2-yl,
NH(CH2)o-3aryl substituted by CO2H, CO2Ci-6alkyl, Het or CH=CHC(O)OC i-6alkyl, CO2H, or C(0)NH(CH2)o-3aryl, where phenyl is optionally substituted by 1 to 3 groups selected from halogen, Ci-6alkyl, NH2, Ci-6alkoxy or CO2H.
15. Use as claimed in Claim 1 of a compound of formula (Id):
Figure imgf000045_0001
or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein R2 is as defined in Claim 1, and R1 is C3-8alkyl substituted by CO2H, C(O)NHCi-4alkyl, C(O)NHS(O)2(Ci-6alkyl),
C(0)NH(CH2)o-3heteroaryl, C(O)NH(CH2)0-3Het, C(O)NHCH(CH3)phenyl or 0(CH2)o-3aryl,
(CH2)i-3C3-8cycloalkyl,
(CH2)3aryl,
(CH2)1-2Het,
(CH2)3heteroaryl, phenyl substituted by SH, SCi-6alkyl or SO2C2-6alkyl,
C(O)NH(CH2)1-3aryl,
C(O)NH(CH2)1-3CO2H, or
C(O)NH(C3-8cycloalkyl) substituted by CO2H or C(O)NHSO2(C i-6alkyl), where the Het groups of (CH2)i-2Het and C(O)NH(CH2)0-3Het are optionally substituted by
Ci-4alkyl, OH or NH2, and where the aryl group of C(O)NH(CH2)i-3aryl is optionally substituted by CO2H, halogen,
Ci-4alkyl or
Figure imgf000045_0002
and where the heteroaryl group of C(O)NH(CH2)0-3heteroaryl is optionally substituted by
Ci-4alkyl.
16. Use as claimed in Claim 1 of a compound of Group II or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, wherein Group II is defined as:
lH-benz[fife]isoquinoline-l,3(2H)-dione, 2-(3-bromophenyl)-6-[(2-hydroxyethyl)amino], 2-(3-chlorophenyl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-butyl-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-[(2-hydroxyethyl)thio]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-7-[(2-hydroxyethyl)amino]-2,3-dihydro-lH-benzo[cfe]isoquinolin-l-one, 2-(3-chlorophenyl)-6-(3-hydroxypropyl)-lΗ-benzo[cfe]isoquinoline-l,3(2Η)-dione, 2-(3-chlorophenyl)-6-(lH-pyrazol-3-yl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione, 3-[6-[(benzylamino)carbonyl]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]hexanoic acid, 6-[(2-hydroxyethyl)amino]-2-[(5-methylisoxazol-3-yl)methyl]-lH-benzo[fife]isoquinoline-l,3(2H)-dione, cis-A- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid,
2-(3-bromophenyl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-[(2-methoxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-(propylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-[(3-hydroxypropyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione, 6-amino-2-(3-bromophenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-[(2-hydroxyethyl)thio]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-(methylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6- { [2-(dimethylamino)ethyl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-(isobutylamino)-lH-benzo[fife]isoquinoline-l,3(2H)-dione, 2-(3-bromophenyl)-6-(ethylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 6-(benzylamino)-2-(3-bromophenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-[(2-phenylethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-[(2-phenoxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione, 2-(3-bromophenyl)-6-[(2-hydroxyethyl)(methyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione, 2-(3-bromophenyl)-6-[(tetrahydroftαran-2-ylmethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-(cyclopentylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-(cyclohexylamino)- lH-benzo[de]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-(isopropylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6- { [2-(methylthio)ethyl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-methoxy- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
N-(2- { [2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} ethyl)acetamide, 2-(3-bromophenyl)-6- { [2-(methylamino)ethyl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-(2-hydroxyethoxy)- lH-benzo[de]isoquinoline- 1 ,3(2H)-dione, 6-[(2-aminoethyl)amino]-2-(3-bromophenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione, 2-(3-bromophenyl)-6-[(cyclopropylmethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 2-(3-bromophenyl)-6-[(pyridin-2-ylmethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, benzyl (2- { [2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} ethyl)carbamate,
6-[(l-benzylpiperidin-4-yl)amino]-2-(3-bromophenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
4-( { [2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}methyl)benzoic acid, trans-4- { [2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid, cis-4- { [2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid,
4- { [2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}piperidinium trifluoroacetate,
6-[(2-hydroxyethyl)amino]-2-phenyl-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-benzyl-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-butyl-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-cyclohexyl-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
6-[(2-hydroxyethyl)amino]-2-isobutyl-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]benzonitrile,
6-[(2-hydroxyethyl)amino]-2-(3-methoxyphenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
6-[(2-hydroxyethyl)amino]-2-(3-methylphenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
6-[(2-hydroxyethyl)amino]-2-[3-(methylthio)phenyl]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(4-bromophenyl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione
6-[(2-hydroxyethyl)amino]-2-[3-(trifluoromethyl)phenyl]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-fluorophenyl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
6-[(2-hydroxyethyl)amino]-2-[3-(methylsulfonyl)phenyl]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(5-bromopyridin-3-yl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]benzenesulfonamide,
2-(2-bromophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3,5-dichlorophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(2,3-dichlorophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(2,5-dichlorophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-chloro-4-fluorophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-chloro-4-methoxyphenyl)-6-[(2-hydroxyethyl) amino]- lH-benzo[cfe]isoquinoline-l,3(2H)-dione,
6-[(2-aminoethyl)amino]-2-phenyl- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, methyl { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} (oxo)acetate,
6-[(l-benzoylpiperidin-4-yl)amino]-2-(3-chlorophenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
6-[(l-acetylpiperidin-4-yl)amino]-2-(3-chlorophenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-chlorophenyl)-6- { [ 1 -(cyclohexylcarbonyl)piperidin-4-yl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)- dione,
2-(3-chlorophenyl)-6- { [ 1 -(phenylsulfonyl)piperidin-4-yl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)- dione,
N-[2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]glycine,
4-( { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}methyl)cyclohexanecarboxylic acid,
2-(3-chlorophenyl)-5-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-[(4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[de]isoquinolin-6-yl]amino}piperidin- 1 - yl)carbonyl]benzoic acid,
4-[(4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}piperidin- 1 - yl)carbonyl]benzoic acid,
N-[2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-5-yl]acetamide,
4-chloro-2-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]benzoic acid,
N-[2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]-2-phenylacetamide,
2-(3-chlorophenyl)-5-(methylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-5-(dimethylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-( { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-5-yl]amino}methyl)pyridinium trifluoroacetate, trans-A- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid,
2-(3-chlorophenyl)-6-(2-oxopyrrolidin-l-yl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
5- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}pentanoic acid, 1 -benzyl-4- { [2-(2-carboxy-5-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}piperidinium trifluoroacetate, (25)-2-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]pentanoic acid,
4- { [2-(3-carboxyphenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}piperidinium trifluoroacetate,
3-[6-[(l-acetylpiperidin-4-yl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-5-bromobenzoic acid,
1 -benzyl-4-( {2-[(l S)- 1 -carboxybutyl]- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl}amino)piperidinium trifluoroacetate, ethyl 2-(6-bromo- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl)- 1 ,3-thiazole-5-carboxylate,
6- { [2-(benzyloxy)ethyl]amino} -2-[(5-methylisoxazol-3-yl)methyl]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)- dione,
6-[(2-hydroxyethyl)amino]-2-[(5-methylisoxazol-3-yl)methyl]-lH-benzo[fife]isoquinoline-l,3(2H)-dione, 3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]benzoic acid, 4-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]benzoic acid, 2-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-4-methylpentanoic acid, methyl cis-A- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylate,
2-(3-chlorophenyl)-6-(3-oxo-2-azabicyclo[2.2.2]oct-2-yl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]benzoic acid, cis-A- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 - methylpiperidinium trifluoroacetate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 -(2- phenylethyl)piperidinium trifluoroacetate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 - propylpiperidinium trifluoroacetate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 -(1 ,3-thiazol-2- ylmethyl)piperidinium trifluoroacetate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 -[4-
(methoxycarbonyl)benzyl]piperidinium trifluoroacetate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 - isopropylpiperidinium trifluoroacetate,
1 -benzyl-4-( {2-[3-bromo-5-(ethoxycarbonyl)phenyl]- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl}amino)piperidinium trifluoroacetate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 -(2-ethoxy-2- oxoethyl)piperidinium trifluoroacetate,
1 -(4-carboxybenzyl)-4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}piperidinium trifluoroacetate,
6-anilino-2-(3-chlorophenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(4-methoxyphenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[cfe]isoquinolin-6-yl]benzoic acid,
4-[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[cfe]isoquinolin-6-yl]benzoic acid,
2-(3-chlorophenyl)-6-(3-fluoro-4-methoxyphenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(2-fluoro-4-methoxyphenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(4-fluoro-3-methylphenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(5-fluoro-2-methoxyphenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-[2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]- lH-pyrazol- 1 -ium trifluoroacetate,
2-(3-chlorophenyl)-6-(3-thienyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, 4-[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[fife]isoquinolin-6-yl]pyridinium trifluoroacetate,
2-(3-chlorophenyl)-6-(3-furyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[fife]isoquinolin-6-yl]pyridinium trifluoroacetate,
2-(3-chlorophenyl)-6-pyrimidin-5-yl- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-[2-(3-chlorophenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[cfe]isoquinolin-6-yl]benzenaminium trifluoroacetate,
2-(3-chlorophenyl)-6-cyclohexyl- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
1 -(carboxymethyl)-4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}piperidinium trifluoroacetate,
1 -benzyl-3- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}pyrrolidinium trifluoroacetate, methyl 4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}benzoate,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}benzoic acid,
2-(3-chlorophenyl)-6-(pyridin-2-ylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(pyridin-3-ylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]hexanoic acid,
3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N,N- dimethylbenzamide,
3- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}benzoic acid,
2-(3-chlorophenyl)-6-[(4-morpholin-4-ylphenyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
6- { [3-(benzyloxy)phenyl]amino} -2-(3-chlorophenyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(quinolin-3-ylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(3-chlorophenyl)-6-(isoquinolin-7-ylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, ethyl (2£)-3-(4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}phenyl)acrylate,
2-(3-chlorophenyl)-6- { [3-(trifluoromethyl)phenyl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
6-[(4-,yec-butylphenyl)amino]-2-(3-chlorophenyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-chlorophenyl)-6- { [4-(trifluoromethyl)phenyl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N- methylbenzamide,
N- {3-bromo-5-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl]benzoyl} -β- alanine,
4-[({3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljbenzoyl} amino)methyl]benzoic acid, c/.y-4-({3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljbenzoyl} amino)cyclohexanecarboxylic acid, 3-({3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H))- yljbenzoyl} amino)cyclohexanecarboxylic acid,
3- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} -NN- dimethylbenzenaminium trifluoroacetate,
3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N- (methylsulfonyl)benzamide,
2-(6-anilino- 1 ,3-dioxo- lH-benzo[fife]isoquinolin-2(3H)-yl)pentanoic acid,
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} -2- methylquinolinium trifluoroacetate, ethyl 3-(6-anilino- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl)-5-chlorobenzoate,
3-(6-anilino- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl)-5-chlorobenzoic acid,
4- { [2-(3-carboxy-5-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 - isopropylpiperidinium trifluoroacetate,
4- { [2-(3-carboxy-5-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino} - 1 -(2- phenylethyl)piperidinium trifluoroacetate,
4-[(4- { [2-(3-carboxy-5-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yl]amino}piperidinium- 1 -yl)methyl]pyridinium bis(trifluoroacetate),
1 -benzyl-4-[(2- {3-bromo-5-[(methylamino)carbonyl]phenyl} - 1 ,3-dioxo-2,3-dihydro- IH- benzo[fife]isoquinolin-6-yl)amino]piperidinium trifluoroacetate,
6-anilino-2-butyl- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
4-[(2-butyl- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl)amino]- 1 -isopropylpiperidinium trifluoroacetate,
3-(6-anilino- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl)hexanoic acid,
4-( {2-[ 1 -(carboxymethyl)butyl]- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl} amino)- 1 - isopropylpiperidinium trifluoroacetate,
2-(3-bromophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinoline-6-carboxylic acid,
2-[ 1 -(carboxymethyl)butyl]- 1 ,3-dioxo-2,3-dihydro- lH-benzofcfeJisoquinoline-ό-carboxylic acid,
3-[6-[(benzylamino)carbonyl]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]hexanoic acid,
2-(5-chloro-2-methoxyphenyl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-(6-anilino- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl)-N-(methylsulfonyl)hexanamide,
1 -isopropyl-4-( {3-[6-[( 1 -isopropylpiperidinium-4-yl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)- yljhexanoyl} amino)piperidinium bis(trifluoroacetate),
1 -isopropyl-4-[(2- { 1 -[2-(methylamino)-2-oxoethyl]butyl} - 1 ,3-dioxo-2,3-dihydro- IH- benzo[fife]isoquinolin-6-yl)amino]piperidinium trifluoroacetate,
2-(5-chloro-2-hydroxyphenyl)-6-[(2-hydroxyethyl)amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-(2,3-dihydro-lh-inden-4-yl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione, 2-(3-chloro-2-fluorophenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
2-(3-bromo-2-methylphenyl)-6-[(2-hydroxyethyl)amino]-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
6-[(2-hydroxyethyl)amino]-2-(4-methylpyridin-2-yl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
3-( { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}methyl)benzoic acid,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-l,3,4-thiadiazol-2- ylhexanamide,
2- { 1 -[2-(3-amino- lH-pyrazol- 1 -yl)-2-oxoethyl]butyl} -6-[(2-hydroxyethyl)amino]- IH- benzo[fife]isoquinoline- 1 ,3(2H)-dione,
2-( {3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)-yl]hexanoyl} amino)- 1 ,3- thiazol-3-ium trifluoroacetate,
3-[({3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanoyl} amino)methyl]pyridinium trifluoroacetate,
2-[({3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanoyl} amino)methyl]pyridinium trifluoroacetate,
4-[({3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanoyl} amino)methyl]pyridinium trifluoroacetate,
3-[2-({3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanoyl} amino)ethyl]pyridinium trifluoroacetate,
5-[2-({3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanoyl} amino)ethyl]- lH-imidazol-3-ium trifluoroacetate,
2-(3-chlorophenyl)-6-(3-hydroxypropyl)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
6-[(2-hydroxyethyl)amino]-2-(3-methylcyclohexyl)-lH-benzo[fife]isoquinoline-l,3(2H)-dione,
N-(2,6-difluorobenzyl)-3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)- yljhexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H))-yl]-N-[2-(lH-l,2,4-triazol-5- yl)ethyl]hexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-(2-pyridin-4- ylethyl)hexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-(lH-indol-6- ylmethyl)hexanamide,
N-benzyl-3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]hexanamide,
N-(2,6-dimethoxybenzyl)-3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanamide,
N-(2,6-difluorobenzyl)-3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)- yljhexanamide, N-(2,6-difluorobenzyl)-3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)- yljhexanamide,
{3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]phenyl}acetic acid,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-[(lR)-l- phenylethyljhexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-[(lR)-l- phenylethyljhexanamide,
N-[(3R,4R)-4-hydroxy- 1 , 1 -dioxidotetrahydro-3-thienyl]-3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- IH- benzo[fife]isoquinolin-2(3H)-yl]hexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-[(l-methyl-lh-pyrazol-4- yl)methyl]hexanamide,
N-(2-chloro-6-methylbenzyl)-3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)- yljhexanamide,
N-(2-fluorobenzyl)-3-[6-[(2-hydroxyethyl)amino]- 1 ,3-dioxo- lH-benzo[cfe]isoquinolin-2(3H)- yljhexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-[(15)-l- phenylethyljhexanamide,
3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)-yl]-N-[(15)-l- phenylethyljhexanamide,
2-butyl-6-(butylamino)- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
2-[({3-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[fife]isoquinolin-2(3H)- yljhexanoyl} amino)methyl]-5,7-dimethyl[ 1 ,2,4]triazolo[ 1 ,5-a]pyrimidin- 1 -ium trifluoroacetate,
1 -benzyl-4-( { 1 ,3-dioxo-2-[ 1 -(2-oxo-2- { [(75)- 1 -phenylethyljamino} ethyl)butyl]-2,3-dihydro- IH- benzo[cfe]isoquinolin-6-yl}amino)piperidinium trifluoroacetate,
1 -benzyl-4-( { 1 ,3-dioxo-2-[ 1 -(2-oxo-2- { [(75)- 1 -phenylethyljamino} ethyl)butyl]-2,3-dihydro- IH- benzo[cfe]isoquinolin-6-yl}amino)piperidinium trifluoroacetate, cis-4-{ { 1 ,3-dioxo-2-[ 1 -(2-oxo-2- { [(75)- l-phenylethyl]amino} ethyl)butyl]-2,3-dihydro- IH- benzo[fife]isoquinolin-6-yl} amino)cyclohexanecarboxylic acid, cis-4-{ { 1 ,3-dioxo-2-[ 1 -(2-oxo-2- { [(75)- l-phenylethyl]amino} ethyl)butyl]-2,3-dihydro- IH- benzo[fife]isoquinolin-6-yl} amino)cyclohexanecarboxylic acid,
2- { 1 -[(benzyloxy)methyl]butyl} -6-[(2-hydroxy ethyl) amino]- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione, trans- 1 -benzyl-4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid,
2-(3-chlorophenyl)-6- { [ 1 -(phenylacetyl)piperidin-4-yl]amino} - lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione,
3-bromo-5-[6-[(2-hydroxyethyl)amino]-l,3-dioxo-lH-benzo[cfe]isoquinolin-2(3H)-yl]benzoic acid, l-benzyl-4-{[2-(3-bromo-5-carboxyphenyl)-l,3-dioxo-2,3-dihydro-lH-benzo[cfe]isoquinolin-6- yl]amino}piperidinium trifluoroacetate,
4-[(4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6-yl]amino}piperidinium- 1 - yl)methyl]pyridinium bis(trifluoroacetate),
4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[fife]isoquinolin-6-yl]amino} - 1 -(3- thienylmethyl)piperidinium trifluoroacetate, c/.y-4-[(2-{3-methyl-5-[(methylamino)carbonyl]phenyl}-l,3-dioxo-2,3-dihydro-lH-benzo[fife]isoquinolin-
6-yl)amino]cyclohexanecarboxylic acid, cis- l-benzyl-4- { [2-(3-chlorophenyl)- 1 ,3-dioxo-2,3-dihydro- lH-benzo[cfe]isoquinolin-6- yljamino} cyclohexanecarboxylic acid,
6-bromo-2-butyl- lH-benzo[cfe]isoquinoline- 1 ,3(2H)-dione.
17. A method of inhibiting hepatitis C virus polymerase and/or of treating or preventing an illness due to hepatitis C virus, the method involving administering to a human or animal subject suffering from the condition a therapeutically or prophylactically effective amount of a compound of any one of Claims 1 to 16, or a pharmaceutically acceptable salt thereof.
18. Use of a compound of any one of Claims 1 to 16, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infection by hepatitis C virus, in combination with one or more other agents for the treatment of viral infections.
19. A pharmaceutical composition comprising a compound of formula (Ic) as defined in Claim 14, or a compound of formula (Id) as defined in Claim 15, or a compound selected from Group (II) as defined in Claim 16, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.
20. A compound of formula (Ic) as defined in Claim 14, or a compound of formula (Id) as defined in Claim 15, or a compound selected from Group (II) as defined in Claim 16, or a pharmaceutically acceptable salt thereof for use in therapy.
21. A compound of formula (Ic) as defined in Claim 14, or a compound of formula (Id) as defined in Claim 15, or a compound selected from Group (II) as defined in Claim 16, or a pharmaceutically acceptable salt thereof.
22. A process for preparing a compound of formula (I) as defined in Claim 1 by the reaction of either
(a) a compound of formula (II) with a compound of formula (III):
Figure imgf000055_0001
(II) (IH)
where R , R , A, B and n are as defined in Claim 1 ; or
Qo) a compound of formula (IV) with a compound of formula (V):
Figure imgf000055_0002
(IV) (V)
where R1, R2, A and B are as defined in Claim 1, and L is a suitable leaving group such as chlorine, bromine or nitro; or
(c) the compound of formula (IV) with a compound of formula (VI):
R2— B(OH)2 (VI)
where R is as defined in Claim 1.
PCT/GB2005/050145 2004-09-07 2005-09-07 Naphthalimide derivatives as antiviral agents WO2006027628A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0419850.3A GB0419850D0 (en) 2004-09-07 2004-09-07 Therapeutic agents
GB0419850.3 2004-09-07

Publications (2)

Publication Number Publication Date
WO2006027628A2 true WO2006027628A2 (en) 2006-03-16
WO2006027628A3 WO2006027628A3 (en) 2006-05-04

Family

ID=33186605

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2005/050145 WO2006027628A2 (en) 2004-09-07 2005-09-07 Naphthalimide derivatives as antiviral agents

Country Status (2)

Country Link
GB (1) GB0419850D0 (en)
WO (1) WO2006027628A2 (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028789A1 (en) * 2005-09-07 2007-03-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Quinazoline derivatives as antiviral agents
JP2008536999A (en) * 2006-03-24 2008-09-11 ロレアル Specific phthalimide dyes, dye compositions comprising at least one dye of this type, methods and uses thereof
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7579468B2 (en) 2005-09-15 2009-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
WO2010080874A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
US7767660B2 (en) 2006-12-20 2010-08-03 Istituto Di Richerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
US7781422B2 (en) 2006-12-20 2010-08-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
US7879797B2 (en) 2005-05-02 2011-02-01 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7973040B2 (en) 2008-07-22 2011-07-05 Merck Sharp & Dohme Corp. Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
US7989438B2 (en) 2007-07-17 2011-08-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Therapeutic compounds
US8101595B2 (en) 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
US8119656B2 (en) 2007-12-07 2012-02-21 The Board Of Regents Of The University Of Texas System Inhibitors of the influenza virus non-structural 1 protein
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8178520B2 (en) 2006-05-15 2012-05-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic compounds as antiviral agents
CN102617573A (en) * 2012-02-23 2012-08-01 北京大学 9-substituted triazole para-naphthalimide derivative, preparation method thereof and application
WO2012115945A1 (en) * 2011-02-21 2012-08-30 The Board Of Regents Of The University Of Texas System Viral inhibitors
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
US8278322B2 (en) 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8309540B2 (en) 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8314062B2 (en) 2006-06-23 2012-11-20 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic compounds as antiviral agents
US8377874B2 (en) 2006-10-27 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8377873B2 (en) 2006-10-24 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8461107B2 (en) 2008-04-28 2013-06-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
CN104311548A (en) * 2014-11-10 2015-01-28 苏州太湖电工新材料股份有限公司 Cadmium ion sensor and functional foamed polyurethane
US9738661B2 (en) 2006-10-27 2017-08-22 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
KR20190055914A (en) * 2017-11-16 2019-05-24 숙명여자대학교산학협력단 Hydrazide-linked naphthalimide derivative and use for imaging a copper pool thereof
CN113717104A (en) * 2021-08-06 2021-11-30 盐城东吴化工有限公司 Preparation and application of leveling cationic fluorescent dye containing long carbon chain

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235045A (en) * 1992-03-19 1993-08-10 Microbiomed Corporation Non-azo naphthalimide dyes
EP0733365A2 (en) * 1995-03-21 1996-09-25 Eli Lilly And Company Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
WO2000031039A1 (en) * 1998-11-25 2000-06-02 Merck Patent Gmbh Substituted benzo[de]isoquinoline-1,3-diones
WO2000055118A1 (en) * 1999-03-16 2000-09-21 Glaxo Group Limited Nuclear receptor arylating compounds
WO2003101998A1 (en) * 2002-06-03 2003-12-11 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives
EP0930883B1 (en) * 1996-10-21 2006-01-11 Allelix Biopharmaceuticals Inc. Neurotrophin antagonists for the treatment of epilepsy, alzheimer's disease and pain

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235045A (en) * 1992-03-19 1993-08-10 Microbiomed Corporation Non-azo naphthalimide dyes
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
EP0733365A2 (en) * 1995-03-21 1996-09-25 Eli Lilly And Company Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer
EP0930883B1 (en) * 1996-10-21 2006-01-11 Allelix Biopharmaceuticals Inc. Neurotrophin antagonists for the treatment of epilepsy, alzheimer's disease and pain
WO2000031039A1 (en) * 1998-11-25 2000-06-02 Merck Patent Gmbh Substituted benzo[de]isoquinoline-1,3-diones
WO2000055118A1 (en) * 1999-03-16 2000-09-21 Glaxo Group Limited Nuclear receptor arylating compounds
WO2003101998A1 (en) * 2002-06-03 2003-12-11 California Pacific Medical Center Nitrogen-based homo-camptothecin derivatives

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COSTI M ET AL: "Naphthalimido derivatives as antifolate thymidylate synthase inhibitors" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 31, no. 12, 1996, pages 1011-1016, XP004071796 ISSN: 0223-5234 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879797B2 (en) 2005-05-02 2011-02-01 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8278322B2 (en) 2005-08-01 2012-10-02 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
WO2007028789A1 (en) * 2005-09-07 2007-03-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Quinazoline derivatives as antiviral agents
US7579468B2 (en) 2005-09-15 2009-08-25 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
JP2008536999A (en) * 2006-03-24 2008-09-11 ロレアル Specific phthalimide dyes, dye compositions comprising at least one dye of this type, methods and uses thereof
US8178520B2 (en) 2006-05-15 2012-05-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic compounds as antiviral agents
US8314062B2 (en) 2006-06-23 2012-11-20 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic compounds as antiviral agents
US8138164B2 (en) 2006-10-24 2012-03-20 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8377873B2 (en) 2006-10-24 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8309540B2 (en) 2006-10-24 2012-11-13 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8377874B2 (en) 2006-10-27 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US9738661B2 (en) 2006-10-27 2017-08-22 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US7781422B2 (en) 2006-12-20 2010-08-24 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
US8101595B2 (en) 2006-12-20 2012-01-24 Istituto di Ricerche di Biologia Molecolare P. Angletti SpA Antiviral indoles
US7767660B2 (en) 2006-12-20 2010-08-03 Istituto Di Richerche Di Biologia Molecolare P. Angeletti Spa Antiviral indoles
EP2494991A1 (en) 2007-05-04 2012-09-05 Vertex Pharmaceuticals Incorporated Combination therapy for the treatment of HCV infection
US7989438B2 (en) 2007-07-17 2011-08-02 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Therapeutic compounds
US8927569B2 (en) 2007-07-19 2015-01-06 Merck Sharp & Dohme Corp. Macrocyclic compounds as antiviral agents
US8119656B2 (en) 2007-12-07 2012-02-21 The Board Of Regents Of The University Of Texas System Inhibitors of the influenza virus non-structural 1 protein
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8461107B2 (en) 2008-04-28 2013-06-11 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
US8080654B2 (en) 2008-07-22 2011-12-20 Insituto di Ricerche di Biologia Molecolare P. Angeletti SpA Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
US7973040B2 (en) 2008-07-22 2011-07-05 Merck Sharp & Dohme Corp. Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors
WO2010080874A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
US8828930B2 (en) 2009-07-30 2014-09-09 Merck Sharp & Dohme Corp. Hepatitis C virus NS3 protease inhibitors
WO2012115945A1 (en) * 2011-02-21 2012-08-30 The Board Of Regents Of The University Of Texas System Viral inhibitors
CN102617573B (en) * 2012-02-23 2014-09-17 北京大学 9-substituted triazole para-naphthalimide derivative, preparation method thereof and application
CN102617573A (en) * 2012-02-23 2012-08-01 北京大学 9-substituted triazole para-naphthalimide derivative, preparation method thereof and application
CN104311548A (en) * 2014-11-10 2015-01-28 苏州太湖电工新材料股份有限公司 Cadmium ion sensor and functional foamed polyurethane
CN104311548B (en) * 2014-11-10 2016-11-16 苏州太湖电工新材料股份有限公司 Cadmium ion sensor and functional polyurathamc
KR20190055914A (en) * 2017-11-16 2019-05-24 숙명여자대학교산학협력단 Hydrazide-linked naphthalimide derivative and use for imaging a copper pool thereof
KR102078439B1 (en) 2017-11-16 2020-02-17 숙명여자대학교산학협력단 Hydrazide-linked naphthalimide derivative and use for imaging a copper pool thereof
CN113717104A (en) * 2021-08-06 2021-11-30 盐城东吴化工有限公司 Preparation and application of leveling cationic fluorescent dye containing long carbon chain
CN113717104B (en) * 2021-08-06 2024-01-02 盐城东吴化工有限公司 Preparation and application of leveling cationic fluorescent dye containing long carbon chain

Also Published As

Publication number Publication date
GB0419850D0 (en) 2004-10-13
WO2006027628A3 (en) 2006-05-04

Similar Documents

Publication Publication Date Title
WO2006027628A2 (en) Naphthalimide derivatives as antiviral agents
AU768720B2 (en) Aminopyrimidines as sorbitol dehydrogenase inhibitors
AU2002220195B2 (en) Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
JP5487214B2 (en) Carbazole carboxamide compounds useful as kinase inhibitors
US7795250B2 (en) Indole derivatives as antiviral agents
TWI376374B (en) Novel coumarin derivatives with antitumor activity
US20080269238A1 (en) Thiazolopyrimidine Derivative
WO2011153588A1 (en) Viral polymerase inhibitors
WO2007028789A1 (en) Quinazoline derivatives as antiviral agents
MX2007004488A (en) N-benzenesulfonyl substituted anilino-pyrimidine analogs.
MX2008013203A (en) Anilino-pyrimidine phenyl and benzothiophene analogs.
AU2004226165A1 (en) Pyrimidin-4-one derivatives and their use as p38 kinase modulators
EP1678160A1 (en) Pyrazine derivatives and pharmaceutical use thereof
AU2013302725A1 (en) 4-heteroaryl substituted benzoic acid compounds as RORgammaT inhibitors and uses thereof
JP2010511727A5 (en)
AU2005321946A1 (en) Enzyme modulators and treatments
CZ2001559A3 (en) Indoloxoacetylpiperazine derivatives exhibiting antiviral activity
JP2010511727A (en) Substituted pyrimidines as adenosine receptor antagonists
CN102171204A (en) 8-substituted isoquinoline derivative and use thereof
WO2011120025A1 (en) Indazolyl-pyrimidines as kinase inhibitors
ES2936481T3 (en) 1H-Indazol-carboxamides as receptor-interacting protein kinase 1 (RIPK1) inhibitors
JP2008545756A (en) 1-methyl-1H-pyrazole-4-carboxamides useful as cancer chemotherapeutic agents
JP2018502141A (en) Quinazoline and quinoline compounds and uses thereof
CA2461100C (en) 4-imidazolin-2-one compounds
WO2016135199A1 (en) Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase